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SUMMARY 
This thesis describes the synthesis of cannabinoid 
derivatives leading to the eventual production of the 
radiotracer ~8-THC-ll-oic acid-[125I]iodohistamide. This 
compound has been used to develop a relatively simple 
radioimmunoassay (RIA) for the detection of cannabinoid 
metabolites in blood and urine. The assay shows good 
sensitivity and broad specificity, detecting the major 
~9-tetrahydrocannabinol (~9-THC) metabolites; ~9-THC-ll-oic 
acid, its O-ester glucuronide and ll-hydroxy-~9_THC. 
The combination of an improved high-performance liquid 
chromatographic separation and the RIA gave a method 
suitable for the separation, characterisation and 
quantification of both parent cannabinoids and metabolites. 
The combined technique is sensitive and reliable and suited 
to routine forensic. analysis. 
These methods have been used to study the 
pharmacokinetics and metabolism of ~9-THC following oral 
ingestion of cannabis resin. ~9-THC-ll-oic acid-O-ester 
glucuronide was identified as a major plasma metabolite and 
was shown to be the princip~\ urine metabolite detected wit} 
the RIA. In contrast, unconjugated ~9-THC-ll-oic acid was 
not excreted in the urine in significant amounts. 
Metabolites could be detected in plasma for up to 5 
days and in urine for up to 12 days after a moderate dose oj 
~9-THC (20mg) in cannabis resin. 
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The plasma half-life for ~9-THC-ll-oic acid and its 
glucuronide were determined as 22 ± 2hr and 21 ± 2hr 
respectively (mean ± SEM, n = 4). The urine half-life for 
total cannabinoid metabolites was found to be 25 ± lhr (mean 
± SEM, n = 4). 
Limited interpretation of plasma total metabolite/~9-
THC concentration ratios was shown to be possible, giving 
an indication of time since ingestion. 
A preliminary experiment has shown that passive 
inhalation of cannabis smoke does not lead to detectable 
concentrations of cannabinoid metabolites in plasma or 
urine. 
iii 
Dedicated to my wife and parents 
iv 
ACKNOWLEDGEMENTS 
I would like to thank the staff of the Central Research 
Establishment (CRE) who have given their assistance and 
advice during the course of this work, and particularly 
Dr A R Allan, Dr R E Ardrey and Dr T S Bal who carried out 
mass spectral measurements. I would also like to thank 
Professor D V Parke, Head of the Department of Biochemistry, 
University of Surrey for allowing this work to be carried 
out in his department. 
I am especially indebted to Dr L J King, Dr P A Mason 
and Dr A C Moffat for their supervision and guidance. 
I am most grateful to the Chemical Defence 
Establishment Committee on the Safety of Human Experiments 
for their recommendations, and to the staff of the Medical 
Division, and Dr R I Gleadle in particular for their 
assistance in the human experiments. I also wish to thank 
my colleagues who submitted themselves as 'guinea-pigs' for 
these experiments, the Laboratory of the Government Chemist 
who provided the cannabis resin, and Chief Technician 
Metcalfe of the Princess Alexandra RAF Hospital, Wroughton, 
Slough, for creatinine analysis. I am especially grateful 
to Mrs C Hearle who so carefully translated my writing into 
this final manuscript, and my wife Yvonne for her help, 
understanding and encouragement. 
Finally I would like to thank the Home Office for the 
opportunity to carry out this work. 
v 
We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started 
And know the place for the first time 
T.S. Eliot 
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CHAPTER 1. GENERAL INTRODUCTION 
Cannabis in perspective 
The Indian hemp plant Cannabis sativa has been known 
and used for several thousand years in the Near and Far East 
where it was cultivated for its narcotic and medicinal 
properties as well as being a valuable source of hemp fibre. 
The introduction of cannabis into Western civilisation, 
however, has been a much more recent phenomenon, occurring 
during the early part of the 1800s possibly through troops 
returning from the Napoleonic Wars in Egypt. 
Cannabis - usually employed 1n the form of a tincture 
enjoyed legitimate medicinal use in the West until as 
recently as the early part of this century when it began to 
be superseded by better understood synthetic medicines. 
Although during these early years it does not seem to have 
been the subject of widespread abuse, the first legal 
control of cannabis misuse in the UK was brought about in 
the Dangerous Drugs Act (1925). Comprehensive control of 
cannabis with regard to its possession and cultivation first 
occurred in 1965 when it was introduced into the Dangerous 
Drugs Act (1965). This date coincides with the beginning of 
the so called "swinging sixties" which saw a great upsurge 
1n the abuse of drugs, especially illicit preparations such 
as LSD and cannabis. Figure 1, which shows the number of 
successful prosecutions in England and Wales for drug 
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offences between 1965-81, gives an indication of the rapid 
increase in cannabis abuse over this period. The large 
number of cannabis prosecutions in recent years (>12,000) 
coupled with the fact that over 80% of all drug prosecutions 
in 1981 involved cannabis, serves to show the extent of the 
cannabis problem in Britain today. 
Number of 
successful 
prosecutions 
(x1000> 
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Figure 1. The number of successful prosecutions for drug 
related offences in England and Wales, 1965-81 .• ; 
cannabis, 0; other drugs. 
With the well established, mind altering properties of 
cannabis and its effects on performance, including driving 
ability, the need for effective legislation controlling 
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cannabis use is obvious. Analytical back-up and the 
scientific expertise afforded by forensic science 
laboratories are necessary prerequisites to the enforcement 
of any drug-related legislation. 
Cannabis Pharmacology and Metabolism 
The cannabis plant contains over 60 cannabinoid 
compounds (Turner et ale 1980), which are defined as 
terpenophenolics having a C21 nucleus. Up until the early 
1960s, the pharmacology of cannabis was studied using crude 
extracts of the plant, or poorly defined preparations of 
cannabinoid compounds themselves. This was due to the 
complex nature and similarity of the natural cannabinoids 
and the poorly developed separative techniques available at 
that time which prevented their separation and 
identification. In 1964 however, Gaoni and Mechoulam (1964) 
reported the successful isolation of the major active 
constituent of cannabis; ~9_trans-tetrahydrocannabinol 
(~9-THC). The structure of this compound is shown in Figure 
2, and is numbered using the dibenzopyran system. This 
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Figure 2. ~9_trans-Tetrahydrocannabinol (~9-THC) 
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numbering system is used by most workers in the field and 
also by Chemical Abstracts. It is used in this thesis in 
preference to the monoterpene system based on p-cymene. 
The isolation of ~9-THC resulted in a massive upsurge 
in the study of cannabis particularly the pharmacology and 
metabolism of the cannabinoids, which has resulted in over 
3000 scientific publications in the 10 years up to 1974. 
The pharmacology of the cannabinoids is complex with a 
number of natural and synthetic compounds showing potential 
for the treatment of pain, epilepsy, nausea (associated with 
cancer chemotherapy), glaucoma and as anti-bacterial agents. 
The pharmacological effects of interest to the forensic 
scientist (both psychological and physiological) are mainly 
due to ~9-THC with possible potentiation or synergistic 
action by other natural cannabinoids or metabolites. These 
effects usually occur within minutes of smoking and may last 
up to 4 hr. Following oral ingestion, the onset of 
pharmacological action is usually delayed by 1-2 hr but may 
persist for up to 6 hr. The only overt effect of cannabis 
intoxication is conjunctival suffusion which is also 
accompanied by increased heart rate (tachycardia). This 
latter effect has been shown to be well correlated with 
subjective effects (Perez-Reyes et ale 1973), and is a good 
indication of the period of pharmacological action. The 
major psychologic, as opposed to physiologic effects include 
a feeling of hilarity, excitement, distorted perception of 
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time, loss of short-term memory, and a general feeling of 
well being or euphoria, usually termed the IIhigh li • Adverse 
effects are usually mild and rare and may include paranoia 
and dysphoria. Cannabis is also known to have a detrimental 
effect on driving ability and other manipulative skills. 
In common with the pharmacology, the metabolism of the 
cannabinoids is also complex, and in certain areas poorly 
defined. The following brief discussion on metabolism will 
be limited to those features having forensic relevance i.e. 
the major metabolic pathways of ~9-THC in man. 
~9-THC has been found to be extensively and rapidly 
metabolised giving rise to around 80 known metabolites. 
Most of this work however has been carried out with animals, 
both 1n V1VO and in vitro - mainly by the research groups of 
Agurell and Harvey. Unfortunately, the high doses of ~9-THC 
used in some animal experiments (Harvey and Paton 1976), up 
to 5000 times the normal human dose (ca. 140 ~g/kg) suggests 
that this work may have little relevance to human 
metabolism. This problem is also compounded by the observed 
differences between the sites of metabolism e.g. liver, lung 
etc. (Widman et ale 1975) as well as between animal species 
(Mechoulam et ale 1976). The work on human metabolism and 
pharmacology has also been complicated to a certain degree 
by the differing routes of administration i.e. smoking, 
oral, i.v. infusion and i.v. injection and in the case of 
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the latter three, by the vehicle used. However, certain 
clear facts regarding the metabolism of ~9-THC in humans 
have emerged. 
Following smoking of ~9-THC (ca. 5-20 mg) - the usual 
route of administration in cannabis users - the parent 
compound rapidly disappears from the blood compartment. 
Levels drop from ca. 50 ng/ml within minutes of smoking to 
ca. 1 ng/ml 2-4 hr after smoking has ceased. During this 
distribution phase, ~9-THC also undergoes extensive 
metabolism. Wall et ale (1972) have identified 
ll-hydroxy-~9_THC, 8u- and 8B-hydroxy-~9_THC and 8u,11- and 
8B,11-dihydroxy-~9-THC ln plasma following oral 
administration of ~9-THC. Cannabinol (CBN) has also been 
detected in blood following ~9-THC administration (McCallum 
1974) and subsequently shown to be a true metabolite of 
~9-THC (McCallum et ale 1975). In general, these neutral 
metabolites, with the exception of ll-hydroxy-~9_THC 
following oral ingestion, are only produced in small 
amounts. A more significant metabolite is ll-nor-9-
carboxy-~9_THC (~9-THC-ll-oic acid) which has been 
identified in plasma at levels exceeding those of ~9-THC by 
Wall et ale (1976) and in urine of cannabis smokers by 
Nordqvist et ale (1977). Wall and coworkers (1976) have 
also observed a large proportion of more polar acid 
metabolites which may correspond to ~9-THC-ll-oic 
acid-a-ester glucuronide (~9-THC-ll-oic acid glucuronide). 
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This metabolite conjugate has been identified in the urine 
of cannabis smokers by Williams and Moffat (1980), where it 
constituted a large proportion of detectable cannabinoid 
compounds, and may well be the major metabolite of ~9-THC in 
man. Presumptive evidence for the presence of significant 
quantities of this metabolite in plasma has also been 
obtained (Law et ale 1981). 
Recently Halldin et al (1982a) detected 13 carboxylic 
acid metabolites in the urine of man following large doses 
of oral ~9-THC. The major compounds identified were 
~9-THC-ll-oic acid and 4'-hydroxy-~9_THC-ll-oic acid, which 
accounted for about 30% of the urinary metabolites. The 
authors detected more polar metabolites, presumably 
conjugates, which were not identified. Further work by 
Halldin et al (1982b) on in vitro metabolism of ~9-THC using 
human livers failed to find ~9-THC-ll-oic acid, the major 
metabolite detected being ll-hydroxy ~9-THC, with 
significant amounts of 8-hydroxylated metabolites. Even 
larger amounts of 8,11-dihydroxylated metabolites were 
produced by a liver whose donor had been treated with a 
metabolic inducer (phenytoin). These results appear to be 
in contradiction to their previous report and other reported 
data (Wall et ale 1981), which indicate ~9-THC-ll-oic acid 
as the major identifiable metabolite of ~9-THC in man. 
Unpublished data from this laboratory (Law 1979) suggest 
that the in vivo metabolic pattern in liver is similar to 
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that observed in blood, viz. ~9-THC-ll-oic acid and its 
glucuronide conjugate predominating. It is possible that 
in vitro metabolism may differ from the in vivo process in 
the human liver. However, it is more probable that the 
experimental procedure used by Halldin and his co-workers in 
the second report may not have allowed the isolation and 
identification of acidic or conjugated metabolites, although 
it may be significant that the authors made no mention of 
these. 
The major known human metabolites of ~9-THC are 
presented in Figure 3. It is to these compounds, and the 
acidic metabolites in particular that any forensic detection 
method or assay should be aimed. 
Detection and Quantification of Cannabinoids in Body Fluids 
Early methods of cannabis detection and quantification 
were directed towards ~9-THC as the major active principle 
of cannabis. Most successful methods involved gas 
chromatography (GC) usually with mass spectrometric (MS) 
detection (e.g. Agurell et ale 1973). The high sensitivity 
and specificity of these methods was only obtained through 
extensive sample preparation usually involving some form of 
column chromatography. 
More recently, a number of specific radioimmunoassay 
(RIA) methods have been reported for the detection of ~9-THC 
in blood (Yeager et ale 1981 and Owens et al. 1981). The 
method of Owens and coworkers utilised a 1251 radiotracer; 
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Figure 3. Structure of 69-THC and its major human 
metabolites. 
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51-iodo-~8_THC the preparation of which was reported while 
this work was in progress (Pitt et ale 1980). Although 
reports on cannabinoid immunoassays date back to Grant et 
ale (1972), the 8 years it took for the development of the 
first 1251 radiotracer (Pitt et ale 1980) must serve as an 
indicator to the difficulty and complexity of cannabinoid 
research. 
The rationa1e behind the measurement of ~9-THC, despite 
its transient nature and low levels, lay in the fact that it 
was the major pharmacological agent present in plasma. 
Thus, measurement of ~9-THC was thought to give an 
indication of the degree of intoxication or impairment of a 
subject. However, recent work on cannabis metabolism and 
pharmacology (Wall et ale 1981, Cochetto et ale 1981, 
Hollister et al. 1981 and Perez-Reyes et ale 1982) has 
indicated poor correlation between plasma ~9-THC levels and 
objective or subjective effects. In one particular report 
(Wall et ale 1981) subjective effects were seen to be more 
highly correlated with the concentration of acidic 
metabolites, although it is known that these compounds are 
inactive (Mechoulam et ale 1973). The value of ~9-THC 
quantification in forensic science is further limited by the 
rapid distribution and metabolism of ~9-THC and the fact 
that it is not excreted in urine. Forensic scientists are 
frequently called upon to analyse urine or blood samples 
taken many hours or days after an alleged offence was 
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committed. In these circumstances the requirement is for a 
broadly specific assay, capable of detecting cannabinoid 
metabolites and thus indicating cannabis use even though 
pharmacological action may long have passed. 
Immunoassay methods i.e. RIA (Williams et ale 1978) and 
enzyme immunoassay (Emit) (Law et ale 1982) can meet this 
requirement through the use of broadly specific antisera 
allowing the detection of a wide range of cannabinoid 
compounds in a single analysis. Immunoassay methods are 
also the first choice for screening purposes. These 
techniques are relatively simple, rapid and cheap to use and 
require the minimum of sample, typically 50-100~1. Thus 
negative samples can be eliminated from further 
investigation without lengthy analysis or the expenditure of 
valuable or limited sample. 
The merits of the various immunoassay systems depend on 
a number of factors, including tracer type e.g. enzyme, 
radio-atom, fluophore etc, ease of automation and 
compatibility with existing laboratory equipment. 
The Syva enzyme immunoassay for cannabinoid detection 
in urlne (Emit-d.a.u.) has been evaluated (Peel and Perrigo 
1981 and Law et ale 1982) and although designed for the 
assay of urine, it can also be applied to the analysis of 
blood through the use of a simple extraction. The high cost 
of the assay (120p/test) however, coupled with the demand on 
the operator when using manual equipment and the poor 
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sensitivity make it unsuited to routine high throughput use. 
In contrast, the manual or semi-automated application of RIA 
to routine screening has been found to be more successful 
both in terms of cost and technical performance. 
RIA for Drug Detection 
As the term implies, radioimmunoassay (RIA) requires 
the use of two reagents; a radio-labelled drug derivative 
(see next section) and an antiserum directed against the 
drug. The antiserum is raised in animals against a 
drug-protein conjugate, termed an immunogen. The 
specificity of the antiserum is ultimately dependent on the 
way the drug molecule is linked to the protein carrier. If 
the main site of metabolic change is occluded, or a 
structural feature common to related drugs is exposed in 
linking to the protein, the antiserum will be broadly 
specific. This will allow detection of metabolites or 
closely related analogues as well as the parent drug to 
which the antiserum was directed. An example of the 
converse approach is shown by the work of Cook et ale 
(1976). A specific THe antiserum was produced by use of the 
conjugate shown in Figure 4. As the 8- and II-positions 
are distal to the point of linkage, this region was well 
recognised by the antiserum. Consequently metabolism in 
this part of the ~9-THC molecule led to poor reactivity of 
the resultant metabolites towards the antiserum. As the 8-
and II-positions are the sites of major metabolic change, 
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NH-BSA 
Figure 4. Immunogen used by Cook et al. (1976) to obtain a 
specific THC antiserum. The drug moiety is linked to bovine 
serum albumin (BSA) through the 51-position. 
the resultant antiserum was relatively specific for 
unchanged ~9-THC. 
RIA is usually carried out by mixing the sample or 
standard with the radiotracer and a limited amount of the 
antibody. A dynamic equilibrium is attained with a fraction 
of both unlabelled drug (sample or standard) and radiotracer 
being bound to the antiserum. As a limited amount of 
antibody is used, only a proportion of the total drug added 
can be bound at any time. Therefore as the amount of 
unlabelled drug is increased, the proportion of labelled 
drug bound to the antibody will decrease. Separation of the 
antibody bound drug from free drug enables the amount of 
labelled drug in either fraction to be determined. The 
concentration of labelled drug in the bound fraction is 
inversely proportional to the amount of unlabelled drug 
added. A standard curve can therefore be constructed and 
the concentration of drug in an unknown sample determined by 
interpolation. 
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The first true drug RIA was reported for digitoxin in 
1968 (Oliver et ale 1968)i since that time the field has 
expanded enormously with well over one hundred different 
drug RIA methods having been reported. Immunoassay methods 
for drug detection and RIA in particular have been well 
reviewed (Landon and Moffat 1976, Butler 1978, and Marks 
et ale 1980). 
The analysis of cannabinoids by RIA has been carried 
out in this laboratory since 1975 using the Guildhay 
antiserum (Teale et ale 1975). Although the original RIA 
method was significantly improved and modified it still 
relied on a tritiated radiotraceri [G-3H] ~9-THC. This 
material was of limited commercial availability and had a 
low specific activity (222 GBq/mmol). The use of this 3H 
tracer necessitated long counting times and involved the 
extra stages and cost related to liquid scintillation 
counting. The use of 1251 radiotracers offers a number of 
major advantages over 3H tracerSi 
(i) much higher specific activities can be obtained, 
up to 81 TBq/mmol for mono-iodinated drugs, 
giving much reduced counting times (30-60s per 
sample) 
(ii) the use of simpler counting procedures due to 
the high energy of the gamma radiation from 1251 
(iii) wider choice of separation method 
(iv) higher sensitivity 
(v) ease of automation 
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The short half-life of 1251 (60 days) compared with 
12.3 yr for 3H, necessitates more frequent preparation of 
iodinated tracers. However 125I-labelled drugs have been 
shown to be stable and suitable for RIA when stored for up 
to 6 months (Law and Mason 1981, unpublished results). 
Labelling of Drugs with 1251 for RIA 
Methods of iodination can be divided into two basic 
-types, the first method involves direct iodination either of 
the drug molecule e.g. morphine (Mason et ale 1980) to give 
2-iodomorphine or a drug metabolite e.g. 4-hydroxypheno-
barbitone (Mason and Law 1981) to give the ortho iodo 
derivative. Iodination is brought about by treating the 
drug compound with Na 125I and an oxidising agent, e.g. 
chloramine-To This method, first described by Hunter and 
Greenwood (1962), involves the oxidation of 1251- to give 
cationic 1251+ which reacts rapidly with a nucleophilic 
centre, e.g. the ortho position of a phenol. 
The second, indirect method employs the use of an 
"iodo-tag" in a procedure often termed conjugation 
labelling. These tag compounds usually contain a phenolic 
function or another ring system susceptible to facile 
electrophilic attack. The tag compound is iodinated prior 
to being linked to the drug molecule, usually in a simple 
reaction of mild conditions. This method has the advantage 
that labile drugs are not subjected to the harsh oxidising 
environment involved in the iodination procedure. Using the 
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conjugation procedure, iodination can also be effected even 
if the drug molecule does not have the necessary 
functionality for direct iodination or other factors 
preclude this approach. As some iodo-tags can be obtained 
commercially this method also avoids the handling of 
potentially hazardous Na l25 I itself. The various methods of 
iodination have been comprehensively reviewed and discussed 
(Bolton 1977 and Seevers and Counsell 19821. 
In preparing the iodo-tracer for RIA, careful 
consideration must be given to the point of attachment of 
the iodine atom or iodo-tag to the drug molecule. 
Replacement of a hydrogen by an iodine atom (the size of a 
benzene ring) or a substituted phenol can lead to 
significant electronic, steric and structural changes in the 
iodinated molecule. These chemical modifications may have 
serious effects on the antibody's recognition of the 
iodinated tracer. Thus production of a successful 
iodo-tracer which will bind to the antiserum will usually 
involve reaction of the drug at the site of, or adjacent to 
that used in preparation of the immunogen. This region of 
the drug molecule should be that which is least recognised 
by the antiserum and thus able to tolerate the structural 
changes associated with iodination. Thus, for use with the 
THC specific antiserum, prepared by Cook et ale (1976), 
5'_[125IJ iodo-~8_THC was found to be most suitable. 
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Examination of the cross-reactivity data for the antiserum 
(Cook et ale 1976) showed substitution at the 5-position to 
be optimal for maximal binding of a radio-labelled 
derivative. Attempts to introduce 1251 into the more 
accessible points of the molecule, i.e. the II-position or 
the phenolic ring would have produced a tracer with much 
reduced cross-reactivity. 
Confirmation and Substantiation of RIA Findings 
Although RIA is well suited to drug screening it 
provides less than unequivocal evidence for the presence of 
a particular drug and/or its metabolites in body fluids. In 
forensic science, where analytical findings may be 
challenged in a court of law, results from screening tests, 
e.g. RIA and Emit, must be confirmed or substantiated by at 
least one other, preferably independent technique. 
Because of the high sensitivity of RIA and the small sample 
provided for analysis this can often prove a major problem. 
In order to avoid methodological discrepancies between the 
screening and confirmatory techniques, the latter method 
should possess similar broad specificity to the RIA. In the 
case of cannabinoids, the assay must detect the major ~9-THC 
metabolites; Il-hydroxy-~9_THC, ~9-THC-ll-oic acid, and its 
glucuronide conjugate at low (ng/ml) levels. When applied 
to cannabinoid metabolite detection however, the common 
analytical tools e.g. thin layer chromatography (TLC) 
(Kanter et ale 1982), gas chromatography (GC) (Whiting and 
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Manders 1982) and high-performance liquid chromatography 
(HPLC), (Abbot et ale 1979 and Valentine et ale 1979), lack 
the necessary sensitivity, or specificity. This problem is 
often aggravated by the small sample of poor quality, e.g. 
haemolysed blood, typically encountered in forensic SClence. 
The one technique which does possess the requisite 
sensitivity and specificity i.e. gas chromatography/mass 
spectrometry (Nordqvist et ale 1977, Rosenfeld and Taguchi 
1976, and Foltz et ale 1979) usually requires extensive 
sample preparation and the use of costly equipment by 
skilled operators. Consequently this method is rarely used 
for routine forensic work. 
The only method to date fulfilling the basic criteria 
of low cost, simplicity etc., whilst allowing detection of a 
wide range of drugs/metabolites is combined HPLC/RIA. This 
powerful, though little used, analytical tool was first 
developed for the detection of LSD and its metabolites in 
body fluids (Twitchett et ale 1978). It combines the 
separating power of HPLC with the sensitivity and group 
specificity of RIA detection and provides a metabolic 
profile of parent drug, neutral and polar metabolites as 
well as metabolite conjugates in a single analytical run. 
The complexity of this pattern can be varied, since it is 
ultimately dependent on the characteristics of the antiserum 
used in the RIA. 
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Research Objectives 
The aim of the work described in this thesis was the 
development of a broadly specific cannabinoid RIA 
incorporating a l25I-labelled tracer. Methods for 
confirming or sUbstantiating the RIA result were also to be 
investigated. The final assay was to be robust and as 
simple as possible, allowing its use in operational forensic 
science laboratories. 
The assay was to be used to examine the disposition and 
elimination of b 9-THC and its metabolites in humans, where 
relevant to forensic science. 
It was hoped that this work would ease the task of 
forensic toxicologists, allowing them to be more efficient 
in providing the police and courts with the information they 
desire, and ultimately se}ving the cause of justice more 
effectively. 
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CHAPTER 2. SYNTHESIS OF A 1251 RADIOTRACER 
FOR USE IN A CANNABINOID RIA 
INTRODUCTION 
The aim of the work described in this section was the 
synthesis of an 1251 radiotracer to be used in a cannabinoid 
RIA incorporating the Guildhay antiserum (Teale et ale 
1975). This antiserum, which was reported to have been 
raised against the immunogen shown in Figure 5, possessed 
two useful features. The antiserum reacted with ~9-THC and 
)""'--NH- BSA 
Figure 5. ~9-THC hemisuccinate-BSA conjugate reportedly 
prepared by Teale et ale (1975). 
the major ~9-THC metabolites (Teale et ale 1975 and Williams 
et ale 1978), including ~9-THC-ll-oic acid and its 
glucuronide. The degree of cross reaction of these 
compounds was also very similar, thus allowing 
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quantification of a number of metabolites using a single 
standard compound. The properties of the antiserum had also 
been well characterised previously in the various 
cannabinoid RIAs used in this laboratory (Williams et ale 
1978 and 1979, Law and Moffat 1980 and Law et ale 1981). 
All these assays employed the B-emitting [G-3HJ-~9_THC as 
radiotracer, with the inherent disadvantages associated with 
this type of assay. 
Previous attempts at production of an iodinated 
radiotracer for use with the Guildhay antiserum were 
unsuccessful (Robinson et ale 1975). Direct iodination of 
the phenol ring of ~9-THC was reported to give the 2-, or 
4-iodo-~9-THC derivative. These compounds however, though 
capable of being bound by the antiserum were highly 
unstable, and useful for only a few days after preparation. 
A second attempt at production of a radiotracer by the same 
group of workers (Robinson et ale 1975) involved linkage of 
~9-THC to GLAT. The latter compound, a synthetic 
polypeptide (glu36-lys25-ala35-tyr5) was connected to ~9-THC 
through a succinyl bridge in an analogous manner to the 
immunogen (Figure 5). The five phenolic tyrosine residues 
in the GLAT molecule, allowed simple and efficient 
iodination by the chloramine-T method. When iodinated 
however, the ~9-THC succinyl-GLAT complex was reported to 
give a radiotracer which bound to the antiserum but could 
not be displaced by native ~9-THC. The radiotracer could, 
21 
however, be displaced by uniodinated ~9-THC-succinyl-GLAT. 
This effect suggested that the antiserum was recognising not 
only the ~9-THC moiety, but also the succinyl linking group 
which was common to the immunogen. This phenomenon, often 
termed "bridge recognition" can be responsible for poor 
sensitivity in those assays where the same linking or bridge 
group is used in both the immunogen and radiotracer. In 
this particular instance, sensitivity was reduced to such an 
extent that the assay was unworkable. 
Following on from this early work, successful 
production of a 1251 radiotracer for the Guildhay antiserum 
was thought to be dependent on three main factors. The use 
of a radioiodinated-tag, with attachment at, or adjacent to 
the phenolic hydroxyl and the use of a bridge other than a 
succinyl group. 
At the onset of this work a single tag was commercially 
available viz 3-(4-hydroxy-3-iodophenyl) propionic 
acid-N-hydroxysuccinimide ester (Bolton-Hunter reagent). 
This compound, which reacts in a facile manner with primary 
and secondary amines, was originally developed for the 
radio-labelling of proteins under mild conditions (Bolton 
and Hunter 1973). The use of a commercially available 
reagent was initially considered preferable as it would 
result in savings of time, and avoid the potential hazards 
associated with free 1251 liberated by oxidation of Na 1251 
during the iodination procedures. Bolton-Hunter reagent had 
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also been successfully used in the production of 
radiotracers for gentamicin (Broughton and Strange 1976) and 
clonazepam (Dixon and Crews 1977). Its use had also been 
investigated for the production of a morphine radiotracer 
(Robinson et al. 1975). In these particular instances 
however, the drug molecules or a metabolite possessed a free 
amino group allowing simple coupling of the unmodified drug 
to the iodo-tag. As 69-THC contains no nitrogen, let alone 
an amino function, initial work was directed towards 
derivatisation to introduce a suitable amino function into 
the cannabinoid nucleus. 
EXPERIMENTAL 
Materials 
Unless stated otherwise all reagents and solvents were 
of Analar grade from BDH Chemicals Ltd, Poole, Dorset. 
Tributylamine (97%), 1,2-diaminoethane, 
tetrabutylammonium bromide, l-amino-3-bromopropane 
hydrobromide, 2-methoxyethylether (diglyme), 4-hydroxyphenyl 
propionic acid, 2-bromoacetaldehyde dimethylacetal, succinic 
anhydride and maleic anhydride were obtained from Aldrich 
Chemical Company Ltd, Gillingham, Dorset. Bovine serum 
albumin (BSA), Tris base, tetrazotised o-anisidine; fast 
blue B salt (FBB), l-ethyl-3(3-dimethylaminopropyl) 
carbodiimide HCI (EDC) were obtained from Sigma Chemical 
Company Ltd, Poole, Dorset. 2-Iodoacetic acid ethyl ester 
was obtained from Fluochem Ltd, Glossop, Derbys., and sodium 
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[125IJ-iodide (6l4MBq/~g) from Amersham International pIc, 
Amersham, Bucks. Cannabinoids were generously provided by 
R.E. Willette of the National Institute on Drug Abuse, 
Rockville, Maryland, USA. Subtilisin A (Subtilisin 
Carlsberg EC3.4.4.l4) 23.7 Anson U/g was obtained from Novo 
Industri A/S, Copenhagen, Denmark. 
Ether and pyridine were redistilled prior to use and 
stored over ferrous sulphate and solid potassium hydroxide 
respectively. Dioxane was passed through a column of 
aluminium oxide (basic, Brockmann grade 1) immediately prior 
to use. 
Cannabinoid antisera were purchased from Guildhay 
Antisera, University of Surrey, Guildford (lot no. 
S133Y/22/5), and from Syva UK Ltd., Maidenhead, as part of 
an Emit-d.a.u. kit for cannabinoid detection in urine. 
Antisera were also obtained as gifts from D.A. Verghise of 
Miles Laboratories Ltd., Slough, Berks, and Sanda Dani of 
The Isler Clinical Toxicology and Pharmacology Unit, The 
Sheba Medical Centre, Tel Aviv, Israel. 
Equipment 
Gamma counting was carried out in a Nuclear Enterprises 
1600 counter which had an efficiency of 61% for 
[129IJiodine. Radioactive spots on paper chromatograms were 
located by cutting the paper into sections and counting 
these in a gamma counter, and also with a Mini Instruments 
type 540 scintillation meter (Alrad Instruments Ltd., 
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Newbury, Berks). To improve resolution of detection, the 
scintillation probe was fitted with a lead shield, 3 rom 
thick, in the centre of which was a small window ca. 2 rom x 
4 rom. 
Low resolution mass spectrometry (MS) was carried out 
using a VG Micromass l6F mass spectrometer fitted with a 
single stage jet separator. The following conditions were 
used: emission, 100 ~A, electron energy, 70 eV, source 
temperature 2000C (unless otherwise stated). Data were 
collected using a VG 2250 data system with the spectrometer 
scanning at 3 s per decade. 
High resolution mass measurements were obtained using a 
Kratos MS 50 mass spectrometer and DS 50 data system. 
Measurements were made under dynamic conditions scanning at 
10 s per decade and were averaged over 10 spectra. The 
following conditions were used: emission, 200 ~Ai electron 
energy, 70 eVi source temperature, 200oC. 
Chromatography 
Gas chromatography (GC) was carried out using a Pye 104 
gas chromatograph (Pye Unicam, Cambridge, Cambs.) Glass 
columns (2 m x 2 rom i.d.) were packed with 2.5% w/w SE-30 on 
Diatomite CQ (100-120 mesh) (Pye Unicam). Nitrogen flow 
rate was 60 ml/min, air and hydrogen flow rates were 
optimised for maximum sens~tivity. Column temperature was 
2400 C or 250o C, injection port temperature 3000C. 
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Retention times (RRT) are quoted relative to ~9-THC, which 
eluted at 4.5 min (2400 C) or 3.3 min (2500C). 
High-performance liquid chromatography (HPLC) was 
carried out using a Waters 6000A HPLC pump, injection being 
made via. a Rheodyne 7120 injection valve fitted with a 20 wI 
or 2 ml sample loop. Column eluate was monitored with a 
Cecil Instruments 212 ultraviolet (UV) monitor at 275 nm, or 
in the case of 1251 labelled compounds, fractions were 
collected for y-counting. 
Analytical HPLC was carried out with a stainless steel 
column (100 mm x 5 mm i.d.) packed with Hypersil 5-0DS 
(Shandon Southern Products Ltd., Runcorn, Cheshire). The 
solvent systems were: 
HI: methanol/water, (82.5/17.5) adjusted to pH 6.1 with 
phosphoric acid solution (1 M) 
H2: methanol/water, (77.5/22.5) adjusted to pH 6.8 with 
phosphoric acid solution (1 M) 
Preparative HPLC was carried out with a stainless steel 
column (250 mm x 8 mm i.d.), packed with 10 wm RP18 (Whatman, 
Maidstone, Kent), the eluent was: 
H3: methanol/water (80/20) 
Thin-layer chromatography (TLC) was carried out on 
silica gel 60 F254, 0.25 mm thickness (Merck), the solvent 
front was allowed to migrate ca. 7 cm. Preparative TLC was 
carried out on the same material, using a 2 mm thick layer. 
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Preparative plates were developed twice in methanol prior to 
use. The solvent front was allowed to migrate ca. 15 cm. 
The following solvent systems were used: 
Tl: Chloroform 
T2: Ether/hexane/acetic acid (50/50/1) 
T3: Methanol/.880 ammonia (98.5/1.5) 
T4: Ethanol/25% v/v aqueous ammonia (80/20) 
Location was effected by the following: 
Ll: Absorption of UV light 254 nm 
L2: Adsorption of iodine vapour 
L3: Fast blue B salt (FBB)i consisting of a ca. 0.5% 
w/v aqueous solution, oversprayed with 0.5 M sodium 
hydroxide to give an intensification of colour 
L4: Marquis reagenti consisting of ca 2% v/v 
formaldehyde in conc. sUlphuric acid. This reagent 
was applied to the TLC plate by means of a dropping 
pipette 
L5: Dragendorftreagenti prepared according to Stead et 
ale (1982). 
Paper chromatography (PC) was carried out using ~fuatman 
papers. Cannabinoid derivatives were chromatographed using 
the Bush B3 system (Bush 1952) given below. 
B3: Petroleum ether (b.p. 80-1000 C), toluene, methanol 
and water were mixed in the ratio 3.3/1.7/4/1 to give a 
biphasic mixture. The two phases were used to saturate the 
atmosphere of the chromatography tank, the upper phase was 
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also used as developing solvent. Papers, No 4 for 
analytical work and purification of radiotracer and 17 M for 
preparative work were run in the descending mode at room 
temperature. Papers were not equilibrated with tank vapour 
prior to development with solvent. 
Histamines were chromatographed using the BAW system 
given below. 
BAW: The solvent was obtained by m1x1ng butanol, acetic 
acid and water in the ratio 120/30/50. No 4 papers were 
used for analytical work and 3 MM for preparative work. 
Location was as previously described or, L6: ninhydrin 
solution (Merck). 
Methods 
69-THC hemisuccinate Initially, synthesis was attempted 
using the method of Teale et ale (1975). 69-THC (50 mg, 0.16 
mmol) was refluxed with succinic anhydride (123 mg, 1.23 mmol) 
in pyridine (4 ml) for 4 hr. The reaction mixture which had 
turned pale yellow was sampled for TLC (TI-T3) which showed 
~9-THC to be the only cannabinoid component present. After 
refluxing for a further 18 hr the mixture was again sampled 
for TLC. System T2 gave two spots Rfs 0.64, FBB pink 
(6 9-THC) and 0.59, FBB mauve. The lower spots matched CBN 
in Rf, no significant low running spots of the expected 
polarity were observed with reagents LI-L3. 
The above procedure was repeated on 1/50 scale (i.e. 
Img ~9-THC) with diglyme or DMF as solvent. The results 
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were qualitatively similar to the above although the 
production of CBN was more pronounced. Prolonged refluxing 
led to the eventual disappearance of both ~9-THC and CBN. 
No detectable cannabinoid products were observed on TLC 
(Tl-T3), detection Ll-L3. 
~9-THC hemimaleate. The procedure used in the preparation 
of the hemisuccinate was repeated using lmg ~9-THC with DMF 
and diglyme as solvents. The results were qualitatively 
similar to those observed earlier, prolonged refluxing again 
leading to disappearance of ~9-THC and CBN with no 
significant products being formed. 
Stability of ~9-THC and CBN. ~9-THC and CBN (1 mg) were 
refluxed in diglyme and DMF (0.1 ml) and repeatedly sampled 
for TLC analysis. After 20 hr reflux there was significant 
loss of both cannabinoids, with no other FBB positive spots 
being detected on TLC. 
~9-THC-0-carboxymethylethyl ester. ~9-THC (50 mg, 0.16 mmol) 
and 2-iodoacetic acid ethyl ester (41 mg, 0.19 mmol) were 
dissolved in dichloromethane (2 ml). Molar sodium hydroxide 
solution (2 ml) containing tetrabutylammonium bromide (64 mg, 
0.16 mmol) was added and the biphasic mixture was stirreo at 
room temperature for 30 min. TLC analysis (TI) indicated 
one main spot, Rf 0.63, which gave a positive reaction with 
iodine vapour, negative reaction with FBB; no THC was 
detected. The aqueous phase was removed and the organic 
layer washed with distilled water (3 x 5 ml), then dried with 
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anhydrous sodium sUlphate. TLC analysis again showed one 
main spot Rf 0.63, but also a strong iodine vapour reaction 
at the origin, probably due to the phase transfer catalyst. 
The dichloromethane solution was reduced in volume by 
evaporation, diluted with hexane and a proportion applied as 
a band to a preparative TLC plate, which was developed in 
system Tl. After drying, the plate showed two UV-absorbant 
bands, the upper band (Rf 0.63) was removed and extracted 
with chloroform. The chloroform was removed under vacuum to 
give a clear oil. TLC (Tl) showed the presence of a single 
spot, which gave a positive reaction with iodine vapour, and 
a very weak reaction with FBB. GLC analysis (2400 C) gave a 
single peak, RRT 1.87. 
Low resolution mass spectrometry (MS) gave the expect.ed 
molecular ion for the ether, m/z 400, and other 
characteristic cannabinoid ions. 
~9-THC-0-carboxymethyl-N-(2-aminoethane)amide. To 
~9-THC-0-carboxymethyethyl ester (15 mg, 38 ~mol) was added 
l,2-diaminoethane (1 ml). After standing at room temperature 
for 5 min, the excess amine was removed under vacuum «400 C). 
to give a clear oily residue which was dissolved in 
dichloromethane (5 ml) and washed with water (2 x 1 ml). The 
dichloromethane solution was dried over anhydrous sodium 
sulphate, and the solvent removed under vacuum ( <400 C). 
Analysis of the clear oil by TLC (Tl) showed the starting 
material to be absent. Further analysis (T2) gave a 
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streaking spot (Rf 0.5) which was UV-absorb_nt and gave a 
posi ti ve reaction with iodine vapour, Dragendor fi reagent and 
Marquis reagent (brown). The spot gave a very weak (pale 
orange) reaction with FBB. 
Analysis by GC (2500 C) gave a single badly tailing peak 
at RRT 3.76. Low resolution MS gave the expected molecular 
ion for the amide, m/z 414 and other characteristic 
cannabinoid ions. 
~9-THC-0-methylether. ~9-THC (20mg, 64 ~mol) and iodomethane 
(10 ~l, 161 ~mol) were reacted under the same conditions as 
for the preparation of the carboxy methyl derivative. The 
reaction of ~9-THC was complete after 45 min, and the 
reaction contained the same non-moving contaminant as 
previously observed on TLC (Tl) as well as a high running 
spot, Rf 0.75. The product was similarly purified by 
preparative TLC (Tl) giving three UV-absorbant bands, the 
upper and most intense band, Rf ca 0.66 was removed and 
extracted with chloroform. The chloroform was removed to 
give a pale yellow oil, which gave a single spot by TLC 
analysis (Tl), Rf 0.75, a positive reaction with iodine 
vapour, and a very weak FBB reaction. GLC analysis (2400 C) 
gave one main peak, RRT 0.73, with two small contaminant 
peaks (RRT 0.69, 0.85): the calculated purity was ca. 95% 
with no ~9-THC detected. 
Low resolution mass spectrometry gave the expected 
molecular ion m/z 328 for the methyl ether with other 
characteristic cannabinoid ions. 
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~9-THC acetate. ~9-THC (122 mg, 0.39 mmol) was heated with 
pyridine (1 ml) and acetic anhydride (0.3 ml) for 2 hr at 
1000C. The volatile components were removed under vacuum 
( <370 C) to give a yellow/brown oil which was dissolved in 
dichloromethane. TLC analysis (Tl) showed complete absence 
of ~9-THC with the major component being a high running spot 
Rf 0.66, giving no reaction with FBB, and a positive 
reaction with iodine vapour. A number of minor low running 
impurities were also present. The acetate was purified by 
preparative TLC (Tl). The upper band (Rf ca. 60) was 
removed and extracted with ethylacetate to give a pale 
yellow oil. TLC analysis showed one component Rf, 0.66, 
giving positive iodine reaction and a positive FBB reaction 
after overspraying with strong sodium hydroxide solution. 
GLC analysis (2400C) indicated one component with RRT 0.89. 
Low resolution mass spectrometry gave the expected 
molecular ion, m/z 356, for the acetate with other 
characteristic cannabinoid ions. 
2-Iodohistamine Histamine was iodinated according to the 
procedure of Tanchou and Slaunwhite (1979). 
Histamine dihydrochloride (4 g, 21.7 mmol) was dissolved 
in water (5 ml) and the pH was adjusted to 7.5 with 40% w/v 
sodium hydroxide solution. Iodine (0.267 g, 2.17 mmol) ln 
ethanol (21 ml) was added dropwise, over 2 hrs with constant 
stirring. After a further hour, the solvent was evaporated 
to dryness under vacuum. The residue was dissolved in water 
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(ca. 5 ml), the solution saturated with ammonium sulphate 
and, after adjusting the pH to 10 with sodium hydroxide 
solution, extracted twice with chloroform/propan-2-ol (3/1, 
25 ml). The combined extracts were concentrated under 
vacuum, and then applied as a band to 3 MM paper and 
chromatographed in the BAW system. Two bands were located 
with ninhydrin, the lower band matching histamine, Rf 0.35. 
The upper band was removed, eluted with methanol and 
re-chromatographed. The upper band was again eluted, and 
2-iodohistamine (49 mg) was obtained after evaporation. This 
was shown to be >99% pure giving a single spot by TLC (T3), 
Rf 0.53, location by UV, iodine and ninhydrin. Low 
resolution MS gave the molecular ion at m/z 237. 
n8-THC-ll-oic mixed anhydride. The carboxyl function of 
n8-THC-ll-oic acid was activated using a modified Erlanger 
procedure (Erlanger et ale 1957). The acid (8.2 mg, 
23.8 ~mol) was dissolved in peroxide-free dioxane (0.5 ml) and 
to this was added tri-n-butylamine (5.8 ~l, 24.4 ~mol) 
followed by isobutylchloroformate (3.15 ~l, 24.0 ~mol). HPLC 
using solvent system HI indicated complete conversion of the 
acid (k ' = 3.4) to the mixed anhydride (k ' = 12.3) after 
75 min. This solution was stored at -18oC and used without 
purification. 
Low resolution MS failed to show the expected molecular 
~on (m/z 444), however a significant ion was observed at m/z 
652 due to a n8-THC-ll-oic acid diester dimer which was 
formed in the mass spectrometer from the mixed anhydride. 
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~8-THC-ll-oic acid-2-iodohistamide. To ~8-THC-ll-oic acid 
mixed anhydride (equivalent to 8.2 mg, 23.8 ~mol of acid) in 
dioxane (0.5 ml) was added 2-iodohistamine (8.5 mg, 35.9 ~ol) 
in dimethylformamide (0.5 ml). Analysis by HPLC using 
solvent H2 indicated complete reaction of the mixed 
anhydride after 10 min, with the formation of ~8-THC-ll-oic 
acid-2-iodohistamide and some regeneration of ~8-THC-ll-oic 
acid. 
The solvent was removed under vacuum to give a brown 
oil which was partitioned between diethyl ether (5 ml) and 
0.025 M phosphate buffer (5 ml, pH 5.1). The aqueous phase 
was washed twice with ether (5 ml) and the combined organic 
extracts evaporated under vacuum «500 C). The residue was 
dissolved in ether and applied as a band to 17 M 
chromatography paper and run in the Bush B3 PC system. The 
band at Rf 0.47 was eluted with methanol. Final 
purification was carried out using preparative HPLC (H3). 
The methanolic extract was injected on to the column in 10 
aliquots (ca. 0.2 ml) and the peak corresponding to the 
iodohistamine conjugate was collected at k' = 6.51. The 
HPLC solvent was removed under vacuum «300 C) to give a 
white crystalline solid (2.35 mg, 19% yield). Low resolution 
MS (source temperature 1900 C) gave the expected molecular 
ion at m/z 563. 
2-[125I]-Iodohistamine. The iodination procedure was a 
modification of that described by Hunter et ale (1975). All 
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reagents were freshly prepared. To histamine dihydro-
chloride (0.83 ~g, 4.5 nmol) in 0.1 M phosphate buffer, pH8 
(10 ~l) was added sodium [ 125rJ-iodide (37 MBq, 0.45 nmol) 
in sodium hydroxide solution (10 ~l) pH7-ll followed by 
chloramine-T trihydrate (60 ~g, 0.213 ~mol) in 0.1 M phosphate 
buffer, pH 8 (10 ~l). The reactants were mixed by vortexing 
ano after 2 min the reaction was stopped by addition of 
sodium metabisulphite (200 ~g, 1.05 mol) in 0.25 M borate 
buffer, pH 8.6 (20 ~l). The crude preparation was suitable 
for use without further purification. 
~8-THC-ll-oic acid 2-[ l25 rJ-iodohistamide. To the 
2-[ l25rJ-iodohistamine solution was added dioxane (40 ~l) 
followed by the mixed anhydride (equivalent to 7 ~g, 
20.3 nmol of acid) in dioxane (10 ~l). The reaction mixture 
was maintained at room temperature for 60 min then diluted 
with 0.25 M tris base solution (0.4 ml) and extracted with 
ether (5 ml) by vortexing for 90 s. The ether extract was 
reduced in volume in a stream of nitrogen (oxygen-free) at 
37oC, in a well ventilated fume hood. 
Assessment of reaction yield using a scintillation 
meter indicated that ~70% of the initial [ 125rJ-iodine had 
been extracted into the organic phase. 
The residue was redissolved in ether (ca. 10 ~l) and 
transferred to No 4 paper as a single spot under a stream of 
nitrogen (oxygen-free). This was chromatographed in the 
Bush B3 PC system until the solvent front had moved 30 cm 
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(about 75 min). The radioactive spot at Rf 0.47 was rapidly 
located using the modified scintillation meter, cut from the 
paper, and the radiolabelled cannabinoid eluted with 
methanol (2 ml); extraction efficiency >99%. Radiochemical 
purity was found to be ca. 90% by HPLC, using solvent H2. 
Radioimmunoassay Compounds were tested for cross-reactivity 
with the Guildhay antiserum using the RIA method of Law and 
Moffat (1980), which employed [G-3HJ-~9_THC as radiotracer. 
Test compounds were dissolved in 70% v/v aqueous methanol 
(concentration range ca. 10 ng-100 ~g/ml) and compared with 
similarly prepared ~9-THC standards. 
Non-covalent "conjugation" of ~9-THC to BSA. The method 
used was taken from Teale et ale (1975). ~9-THC (7 mg, 
0.022 mmol) was dissolved in dimethylformamide (0.5 ml). To 
this solution was added O.lM phosphate buffer, pH 7.4 (10 ml), 
(prepared from 13.24 g KH2P04 and 0.383 9 Na2HP04 per litre) 
containing BSA (25 mg), Cohn fraction V (Sigma product code 
A8022) followed immediately by EDC (12 mg). The mixture, 
which went white and cloudy on adding the buffer was stirred 
at room temperature for 30 min. A further portion of EDC 
(4mg) was added and the solution was stirred continuously 
overnight (22 hr) at room temperature. 
The solution was extracted with ether (3 x 10 ml) by 
gentle shaking in a centrifuge tube (25 ml). The extraction 
process was carried out gently to avoid excessive emulsion 
formation, however centrifugation was necessary to give 
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clean separation of the two phases. The BSA formed a 
gelatinous layer at the aqueous/organic interface. 
To extract the residual ~9-THC, the excess ether was 
evaporated under nitrogen and the aqueous adjusted to pH ~7 
with 40% sodium hydroxide (ca. 4 drops). The solution was 
then buffered (pH 10-11) with Tris base (50 mg), and after 
addition of the proteolytic enzyme Subtilisin A (1 mg), the 
temperature was raised to 50-60oC in a water bath for 60 min. 
After cooling the pH was adjusted to ca. 5 with conc. 
hydrochloric acid (0.1 ml) and the aqueous solution was agaln 
extracted with ether (2 x 10 ml). 
The volumes of the ether extracts were adjusted to 10 ml 
before analysis for ~9-THC by GC, as previously described. 
Quantification was based on peak height measurements. 
RESULTS AND DISCUSSION 
An ether linkage to the phenolic hydroxyl of ~9-THC was 
initially investigated, to avoid the problem of "bridge 
recognition" encountered by Robinson et ale (1975), using a 
phenolic hemiester derivative. However, reaction to give 
the amino ether derivative (Figure 6) was unsuccessful, 
presumably due to the low reactivity of the alkylating 
reagent; l-amino-3-bromopropane. A second less direct 
attempt at introducing an amino group envisaged the reaction 
scheme shown in Figure 7. The final stage of reductive 
amination, could be carried out in relatively high yield 
without isolation of the intermediates. Once again the 
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Figure 6. l-(O-~9_THC)-3-aminopropane 
BrCH 2CH(OC 2H 5)2 I 
--------1.~1 I 
Figure 7. Reaction scheme for the preparation of a ~9-THC 
amino/ether derivative via. an acetal intermediate. 
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+ reflux in 
pyridine 
h-THC 
(i) activation of acid 
(ii) NH 2CH 2CH 2NH 2 
Figure 8. Reaction for the preparation of ~9-THC amino 
derivatives via. hemiester intermediates. 
desired product; the acetal was not obtained. This 
confirmed the poor reactivity of the bromoalkyl link towards 
nucleophilic attack by the phenolate ion of ~9-THC. More 
reactive iodoalkyl reagents were considered, however no 
suitable compounds with the necessary functionality could be 
located in the commercial literature. As an alternative, an 
ester linkage to the phenolic hydroxyl was investigated as 
an indirect means of introducing an amine function into the 
~9-THC molecule (Figure 8). To reduce or avoid the problem 
of bridge recognition, the use of substituted succinic 
anhydride derivatives or maleic anhydride was considered. 
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Reaction of ~9-THC with succinic or maleic anhydride 
under the conditions described by Teale et ale (1975), 
failed to give the expected hemiesters. Prolonged reaction 
at elevated temperature resulted in the formation of CBN, 
with the gradual decomposition and disappearance of both 
this compound and ~9-THC. Control experiments showed this 
disappearance to be independent of the presence of the acid 
anhydrides. Further experiments with modified reaction 
conditions indicated that contrary to the report by Teale 
and his co-workers, the hemisuccinate could not be formed by 
the direct reaction of ~9-THC with succinic anhydride. As 
Teale and his colleagues did not isolate nor characterise 
the proposed hemisuccinate, their reported synthesis must 
remaln in doubt. This statement is supported to a certain 
extent by other reported work concerning phenolic 
hemisuccinates. Morphine, which bears an allylic and a 
phenolic hydroxyl gives only the allylic hemisuccinate when 
refluxed with succinic anhydride in pyridine (Wainer et ale 
1972a and 1972b and Simon et ale 1972). The phenolic 
hemisuccinate of oestra-3,17B-diol is also difficult to 
prepare, and the resulting compound shows poor stability 
towards hydrolysis (Exley and Woodhams 1976). Other work 
however, (Tsui et ale 1974) has shown ~9-THC-hemisuccinate 
to possess some stability and to be capable of eliciting an 
antibody response when injected into sheep in the form of a 
BSA conjugate. 
40 
During the course of this work a commercial source was 
discovered for a functional iodo-alkyl, thus allowing 
further investigation of the more stable phenolic ether 
derivatives. Using phase transfer catalysis, ~9-THC reacted 
efficiently, and rapidly with 2-iodoethyl acetate to give 
the O-carboxylmethyl ethyl ester (Figure 9). Although phase 
transfer catalysts are normally employed in catalytic 
quantities, i.e. 3-5 mole% (Freedman and Dubois 1975), the 
purity of the ether-linked ester, and speed of reaction were 
improved by use of an equimolar quantity. 
The ester underwent rapid and clean amide formation 
with l,2-diaminoethane to give the desired amino derivative; 
Figure 9. ~9-THC-O-carboxymethyl ethyl ester. 
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Figure 10, which required the minimum of purification. 
Assessment and characterisation of the ester and amide with 
the Guildhay antiserum gave a surprising result, in that 
both compounds cross-reacted much less than expected, and 
less than 1/300 that of ~9-THC (Table 1). These results 
were unexpected since it was anticipated that modifications 
to the phenolic hydroxyl should have had little effect on 
the antibody recognition of these derivatives. The marked 
loss of reactivity was shown to be independent of the ether 
Figure 10. ~9-THC-0-carboxymethyl-N-(2-aminoethane) amide. 
linkage since ~9-THC acetate also showed low cross-
reactivity, as did the simplest possible derivative, the 
O-methyl ether (Figure 11). The results obtained with these 
two model compounds (Table I), were a clear indication that 
the free phenolic hydroxyl group was a major antigenic 
determinant, being necessary for avid binding to the 
antiserum. 
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Figure 11. ~9-THC-O-methyl ether and ~9-THC acetate. 
The weak cross-reactivities of the phenolic 
derivatives, coupled with the lack of reaction of ~9-THC 
with succinic anhydride suggested that the Guildhay 
antiserum had not been raised in the manner described. This 
was supported by re-examination of cross-reactivity data 
(Williams et ale 1978) which showed the antiserum to be 
insensitive to quite significant changes at the 9- and 11-
positions. These are sites which are remote from the point 
of attachment in the reported immunogen, and such 
modifications would have been expected to produce a 
significant loss in reactivity. Furthermore, the overall 
cross-reactivity pattern was very similar to that observed 
for an antiserum raised against a ~9-THC derivative 
conjugated through the II-position (Teale et ale 1979). The 
slow and poor response of the immunised animals also 
suggested poor quality of the immunogen. 
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Although the amide derivative was capable of being 
linked to Bolton-Hunter reagent through the free primary 
amine, the low reactivity of the derivatives would give a 
tracer with poor affinity for the antiserum. This factor 
would limit assay sensitivity and result in a non-robust 
assay, consequently this line of research was not 
investigated further. 
TABLE 1 
The relative reactivity of ~9-THC derivatives 
Compound 
~9-THC-0-carboxymethyl 
ethyl ester 
~9-THC-0-carboxymethyl-N­
{2-aminoethane)amide 
~9-THC acetate 
~9-THC-0-methyl ether 
Relative reactivity* 
1.0 
850 
300 
25 
350 
*Relative reactivity is defined at 50% depression of zero 
binding, equivalent to ca 4 ng/ml ~9-THC. 
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Although it was difficult to rationalise certain 
aspects of this data with the bridge recognition problem of 
Robinson et ale (1975), consideration of all the data 
suggested that the immunogen prepared by Teale and his 
co-workers, was in fact a non-covalent association of ~9-THC 
with BSA; the molecules presumably being held together by 
hydrophobic interactions. 
This "pseudo" or "non-covalent" conjugation was 
demonstrated to be a real phenomenon. Under the conjugation 
conditions applied by Teale et ale (1975), ~9-THC was found 
to bind non-convalently to BSA and to be resistant to ether 
extraction. Using their conditions, only ca. 36% of the 
~9-THC could be extracted (Table 2). The residual 64% 
corresponding to 4.5 mg in the experiment reported here 
corresponds to a hapten/protein ratio of 36, this is 
TABLE 2 
Extraction of ~9-THC before and after hydrolysis of a 
non-covalent ~9-THC-BSA conjugate 
Extraction 
number 
1 
2 
3 
4* 
5* 
*After hydrolysis 
~9-THC 
Test 1 
16 
12 
10 
57 
5 
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extracted (% ) 
Test 2 
15 
11 
9 
59 
6 
comparable to the figure quoted by Teale et al. (1975) of 
25. It is to be presumed that ~9-THC was bound in such a 
manner that the 8-, 9-, and Il-positions were occluded while 
the hydroxyl at the I-position was exposed, thus giving rlse 
to the observed cross-reactivity pattern. Preliminary 
experiments with ~9-THC and BSA suggested that the degree of 
binding was dependent on a number of factors, viz. degree of 
extraction, molarity of buffer, BSA preparation - Sigma 
Chemical Co. list five fraction V preparations. As none of 
these parameters were defined, a number of assumptions and 
selections had to be made in the present experimental work. 
The BSA preparation was chosen from the five listed, because 
of its pronounced binding of a radiotracer when used in a 
cannabinoid RIA. This work however, clearly demonstrates 
that under certain conditions pseudo-conjugation of drug and 
carrier-protein can occur, leading to poor titre antisera 
and inexplicable cross-reactivities. This clearly 
demonstrates the need to isolate and characterise drug 
derivatives, and immunogens at all stages in their 
preparation. 
The negative aspects of this previous work, coupled with 
the known cross-reactivities of the antiserum, indicated the 
8-, 9-, 10- or Il-positions of ~9-THC to be the best points 
for substitution to give a suitable radiotracer. However, 
this line of investigation was hampered by a shortage of 
suitably reactive compounds, i.e. the 8- or ll-hydroxylated 
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metabolites or ~9-THC-ll-oic acid. Attempts at derivatising 
~9-THC at the 9-position through formation of a 
thiopropionic acid link (Cook et ale 1974) were unsuccessful 
through instability of ~9-THC under the necessary reaction 
conditions (Figure 12). 
Although ~9-THC-ll-oic acid was virtually unobtainable, 
a small sample of ~8-THC-ll-oic acid was obtained during the 
course of this work. The presence of a reactive carboxyl 
hv or A 
Figure 12. Reaction scheme for the preparation of a 
thiopropionic acid derivative of ~9-THC. 
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function at the II-position made this compound a most 
suitable starting point for synthesis of a radiotracer. 
The method described for the activation of 
~8-THC-ll-oic acid to give the mixed anhydride (Figure 13) 
was relatively quick and simple with the anhydride being 
eaOH 
2-iodohistamine 
F ' 13 Reaction scheme for the preparation of 19ure . ..' d h d . de ~8-THC-ll-oic acid-2-iodohistamlde Vla. the mlxe an Y rl 
derivative. 
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produced in high yield. This compound reacted with 
2-[125I]-iodohistamine to give two major radioactive 
derivatives. It proved extremely difficult using a variety 
of TLC systems to obtain satisfactory or reproducible 
separation of these compounds. However excellent separation 
of all the radioactive and non-radioactive compounds was 
obtained using the Bush B3 PC system (Table 3). The two 
TABLE 3 
Rf of compounds on Bush B3 system 
Compound 
~8-THC-ll-oic acid 
mixed anhydride 
~8-THC-II-oic acid 
~8-THC-II-oic acid-
2-iodohistamide 
Isobutyl-2-(2-iodoimidazo)-
4-yl ethylcarbamate 
~8-THC-Il-oic acid histamide* 
2-Iodohistamine 
Histamine 
Na[125I] 
Rf 
0.97 
0.66 
0.47 
0.13 
0.12 
0 
0 
0 
Colour with 
FBB reagent 
Pink 
Pink 
Pink 
Mauve** 
Pink 
Red** 
Orange** 
* This compound was prepared by the reaction of 
~8-THC-ll-oic acid mixed anhydride and histamine and 
was tentatively identified by its chromatographic 
properties and FBB colour reaction. 
**Gave colour only after overspray with sodium hydroxide 
solution (0.5 M). 
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radioactive compounds were identified by comparison with 
their non-radioactive analogues as ~8-THC-ll-oic 
acid-2-iodohistamide the desired radiotracer, and isobutyl-
2-(2-iodoimidazo)-4-yl ethylcarbamate (Figure 14). The 
latter compound was identified by high resolution MS which 
gave a molecular ion at m/z 337.0278 (ClOH1602N31 requires 
337.02·67). This compound was formed through attack by 
iodohistamine on the isobutoxy bearing carbonyl group of the 
mixed anhydride. This side reaction was also responsible 
for the regeneration of the starting compound, the free 
carboxylic acid. 
The method used initially for conjugation of 2-[1251J 
iodohistamine to ~8-THC-ll-oic acid was that of Nars and 
Hunter (1973) and Hunter et ale (1975). However the 
procedures gave a low yield of the desired product and 
Figure 14. 1sobutyl-2-(2-iodoimidazo)-4-yl ethylcarbamate. 
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significant quantities of the radioactive by-product. 
Reduction in the pH of the conjugation medium to 4.2 by 
replacing sodium hydroxide with a buffer solution increased 
the ratio of the radioactive species; tracer/by-product from 
0.4 to >2. 
The procedures reported by Hunter and his coworkers 
also involved activation of ca. 2.5 mg of the carboxy 
bearing antigen, although only ca. 35 ~g of this was 
actually used in the coupling procedure. This somewhat 
wasteful approach to the synthesis of the radiotracer could 
not be tolerated using rare cannabinoid metabolites. 
Activation of 35 ~g of ~8-THC-ll-oic acid was examined and 
found to be feasible, giving good yields of the mixed 
anhydride and ultimately the radiotracer. A more 
satisfactory approach however was preparation of the mixed 
anhydride on the low milligram scale and storage of the 
product for subsequent use in aliquots over a prolonged 
period. When stored in dioxane at -18o C, the mixed anhydride 
was found to be relatively stable with little decomposition 
«5%) over 6 months, as determined by HPLC (HI). 
During the activation and conjugation steps, control of 
temperature «lOOC) as originally described by Erlanger ~ 
ale (1957) and subsequently used by many other workers (e.g. 
Cook et ale 1974 and Stanczyk and Goebelsmann 1981) was 
found to be unnecessary. It was noted however that reducing 
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the volume of dioxane in the conjugation reaction from 50 ~l 
to 10 ~l resulted in poor reaction efficiency and the 
formation of a large number of radioactive species. 
The Bush B3 PC system proved extremely convenient for 
isolation of the radiotracer following chromatography, as it 
could be eluted from the paper in >99% yield. This 
procedure was also preferable to purification by TLC since 
it avoided the potential risk of handling radioactive silica 
gel dust. Decomposition of the radiotracer on PC (or TLC) 
media was reduced by spotting the chromatography paper (or 
plate) under a stream of nitrogen. Once extracted into 
methanol, however, the radiolabelled cannabinoid was found 
to be extremely stable, with no significant radioactive 
impurities being produced after storage at 40C for 3 months. 
Tanchou and Slaunwhite (1980) recently depreciated the 
mixed anhydride procedure (Erlanger et ale 1957) in favour 
of activation of carboxylic acids by N-hydroxysuccinimide 
ester formation when preparing radiotracers from 
2-[ 125r]iodohistamine. The mixed anhydride reaction as 
described here would appear to offer similar advantages to 
ester formation. Once prepared the mixed anhydride is 
stable and reacts to give a radiotracer in relatively high 
yield (about 50%). The preparation is simple and takes 
about 2.5 hr including chromatographic purification and 
extraction. 
The use of the chromatographic separation for 
purification gave a tracer with good radiochemical purity 
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and high specific activity (ca. 73 TBq/mmol), the latter 
feature being a prerequisite for any sensitive RIA 
procedure. The tracer was found to bind avidly to four 
different cannabinoid antisera (see Chapter 3) viz S Dani 
(personal gift), Emit, Guildhay and Miles Yeda, the last 
three of which are commercially available. As these 
antisera possess differing specificities, the radiotracer 
has potential for the development of a number of broadly 
specific cannabinoid RIA's using commercially available 
reagents. 
CONCLUSIONS 
The final preparation of the radiotracer ~8-THC-ll-oic-
2-[l25Jiodohistamide was comparatively simple, and coupled 
with a chromatographic separation, the compound was isolated 
in relatively high purity (ca. 90%). This tracer showed 
excellent radiochemical stability, and was found to bind to 
four different cannabinoid antisera. Its use will therefore 
aid the development of a broadly specific l25I-RIA, based on 
commercially available reagents. The inclusion of 1251 as 
radioactive marker should allow a more flexible approach to 
the assay conditions (e.g. separation method) and glve 
improved sensitivity when compared with RIAs based on 
tritiated radiotracers. 
This iodine labelled cannabinoid radiotracer is only 
the second to be reported, and the first for use with 
broadly specific antisera capable of detecting ~9-THC 
metabolites. 
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CHAPTER 3. DEVELOPMENT AND EVALUATION OF A BROADLY 
SPECIFIC RIA INCORPORATING A l25I-RADIOTRACER 
INTRODUCTION 
In the development of the RIA procedure, the lipophilic 
nature of the radiotracer (typical of cannabinoid compounds) 
presented a major problem due to limited aqueous solubility. 
Similar problems in the analysis of THC and/or its 
metabolites using 3H-tracers had been previously overcome by 
inclusion in the assay buffer of various solubilisers, e.g. 
Triton X-405 (Teale et al. 1975), methanol (Williams et al. 
1978) and bovine serum albumin (BSA) (Cook et al. 1976). 
The detergents Tween-80 (Toss 1981) and Triton X-305 (Albro 
et al. 1979) have been found to be similarly useful in 
reducing non-specific binding in the RIA of the lipophilic 
compounds 25-hydroxyvitamin D and chlorinated dibenzo-p-
dioxins. In the dioxin assay, Triton X-305 was the only one 
of a number of detergents investigated which give efficient 
solubilisation of tracer while allowing access to antibody. 
The animal protein gelatin is also a common additive in 
steroid RIA buffers being present to minimise non-specific 
binding. 
The degree of non-specific binding is however dependent 
not only on the assay medium but also the type of assay tube 
used (Kubasik et al. 1976; Christensen et al. 1978). This 
is especially important with cannabinoid type compounds, 
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slnce ~9-THC has been shown to bind strongly to glass 
(Garrett and Hunt 1974~ Cook et ale 1976) and plastics 
(Garrett and Hunt 1974). 
One of the major problem areas in the development of a 
RIA is selection and optimisation of a suitable method for 
separation of the bound and free fractions. 
Separation methods can be broadly divided into four 
main categories, viz. 
(a) chromatography, filtration and extraction 
(b) adsorption of either bound or free fraction 
(c) fractional precipitation of bound fraction 
(d) immunological precipitation of bound fraction 
Hany variations and examples of these methods are used 
and they have been the subject of discussion and review 
(e. g. Ratcliffe 1974~ Van Vunakis 1980). They vary 
greatly in their cost, complexity, ease of use, general 
applicability and ease of automation. However, they all 
have the same basic aim. The free and antibody bound tracer 
must be separated rapidly and efficiently without disturbing 
the dynamic equilibrium and thus introducing misclassifi-
cation errors. Most methods are also aimed at reducing 
non-specific binding to a minimum, although this feature 1S 
as much a function of the antigen itself as of the 
separation method. 
In any assay designed for screening large numbers of 
samples (e.g. cannabinoid RIA), simplicity and low cost, are 
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two important criteria. It was to these ends that initial 
experiments were directed. 
One of the most widely used and relatively simple 
separation methods involves adsorption of unbound antigen on 
to charcoal. This method of separation has been used 
previously in a number of RIA methods for cannabinoids 
(Teale et ale 1975; Cook et ale 1976; Chase et ale 1976; 
Soares and Gross 1976; Williams et ale 1978; Law et ale 
1979; Yeager et ale 1981). The charcoal is used in either 
activated form or more usually after coating with a high 
molecular weight substance (e.g. dextran or bovine gamma 
globulin) to reduce adsorption of antigen/antibody complex, 
and hence reduce misclassification errors. This method, 
although relatively simple, suffers a number of disadvantages 
which depreciates its general usefulness. The addition of 
dextran-coated charcoal suspensions is relatively slow, 
tedious, difficult to automate and suffers from poor 
reproducibility. More importantly the separation shows a 
critical time-dependence in terms of specific binding, 
especially with low avidity antisera typical of cannabinoid 
assays. Small variations in charcoal contact time 
produce significant changes in the level of binding. This 
phenomenon effectively limits assay sensitivity and 
necessitates the separation to be carried out in small 
batches of tubes (ca. 20) to maintain a constant contact 
time: this is both tedious and time consuming, and was 
considered unsuitable for use in this assay. 
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A simple method of fractional precipitation which was 
investigated involves the use of polyethylene glycol 
6000 (PEG). In this method, first described by Desbuquois 
and Aurbach (1971), separation is effected by addition of an 
equal volume of ca. 25% w/v aqueous PEG to the assay 
solutions. Denaturation of the gamma globulin fraction is 
instantaneous and precipitation occurs on standing or after 
centrifugation. Although the unbound antigens (polypeptide 
hormones mol. wt ~8,600) were not affected in the assays 
studied, the authors specified careful examination of such 
factors as; pH, presence or absence of certain ions etc. 
when applying PEG separation to a new assay. Examining 
separation by PEG, in the RIA of T3 and T4, Sourgens et ale 
(1979) found pH, buffer type, ionic strength and carrier 
protein to be important factors in effective separation and 
analysis. They did not however vary the final concentration 
of PEG from 12.5% w/v as originally suggested by Desbuquois 
and Aurbach. This concentration of PEG is approximately 
that which is generally recommended for separation in RIA 
(Chard 1981). However it is probable that the optimum 
concentration for small molecule RIA may be nearer 18% w/v 
as was recently reported by Rutterford and Smith (1980) in 
the RIA for diazepam. 
EXPERIMENTAL 
Equipment general 
An Eppendorff Mu1tipette 4780 (Anderman and Co., East 
Moseley, Surrey) was used for all repetitive pipetting and 
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an SMI micro-pettor glass capillary pipette (Alpha 
Laboratories, Eastleigh, Hants) was used for the 
manipulation of small volumes (20-50 ~l). 
Centrifugation was carried out in an Eppendorf 5413 
centrifuge (Anderman and Co); acceleration 9,000 xg, 40 
sample capacity, or a Quickfit microcentrifuge, acceleration 
14,000 xg, 12 sample capacity. 
Gamma counting was carried out using a Nuclear 
Enterprises 8313 dual beta and gamma counter and a Nuclear 
Enterprises 1600 gamma counter (efficiency 61% for 1291). 
For use in RIA the NE1600 was interfaced to a Commodore PET 
3032 microcomputer, and data were processed using an Amersham 
curve fitting routine (Wilkins et ale 1977). 
Solubilisation of radiotracer 
Materials 
Unless stated otherwise all proteins and detergents 
were of general laboratory grade obtained from either Sigma 
or BDH. Fluorad FC134 and FC128 were obtained from Chas. 
Page and Co. Ltd., London. Buffer solutions were prepared 
according to standard formulae (Diem and Lenter 1970). 
Methods 
Radiotracer (~8-THC-ll-oic acid-2[125I] iodohistamide) 
was dissolved in aqueous methanol (50% v/v) to give ca. 
15 Kcpm/ 0.05 mI. A 0.05 ml aliquot of the tracer solution 
was pipetted into duplicate sets of assay tubes and 0.45 ml 
of the appropriate solubiliser solution added. 
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The solubilisers were prepared in O.lM phosphate 
buffer, pH 7.4 , with the exception of methanol which was 
prepared in distilled water. Detergent solutions were 
prepared at least 48 hr prior to use to allow stable micelle 
formation. 
The reagents were mixed by vortexing then incubated at 
room temperature for 90 min. Half of the liquid from the 
first tube (ti) was transferred to a second tube (tii) and 
the tubes counted in a gamma counter. The percentage of 
radioactivity (X), bound to the tube (ti) was calculated, 
using the equation given below: 
X = 
R = 
(l-R) 
(l+R) x 100 
cpm in tube (i) 
cpm in tube (ii) 
Selection of assay tubes 
Materials 
Polypropylene assay tubes (ca. 1.5 ml) with attached 
closures were obtained from Hughes and Hughes, Romford, 
Essex (2 batches); Alpha Labs, Eastleigh, Hants; Precision 
Machine Engineering Ltd., South Harrow, Middx and 
Gordon-Keeble Ltd., Duxford, Cambridge. Polystyrene tubes 
(55 x 12 mm diameter, 3.5 ml) were obtained from W. Sarstedt, 
Leicester, Leicestershire. Standard laboratory soda glass 
tubes (ca. 70 x 10 rom dia) were used after washing with 
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methanol, and after treatment with dichlorodimethysilane (2% 
v/v) in dichloromethane followed by washing with methanol. 
Method 
As previously described 
Solubilisation of radiotracer under assay conditions 
Method 
The RIA method used was a modification of that 
described by Law and Moffat (1980). 
Antiserum (Lot no 133Y/22/5, from Guildhay Antiserum, 
University of Surrey, Guildford, Surrey) was diluted to 
1/320 in phosphate buffer containing 2% PVP-40. Radiotracer 
was dissolved in aqueous methanol (40% v/v) to give ca. 10 
Kcpm/0.02 ml. 
The assay was set up as indicated (Table 4), where a 
reagent was omitted, the appropriate diluent was added in 
its place. 
Evaluation of dextran coated charcoal as separation agent 
Method 
The method was as previously described (Law and Moffat, 
1980) except that the [3HJ-THC-tracer was replaced by the 
[125IJ-tracer at a concentration of ca. 22 Kcpm/O.l ml. 
After addition of dextran-coated charcoal the tubes were 
shaken at room temperature for between 1-12 min prior to 
centrifugation at 14,000 xg for 30 s. Aliquots (0.25 ml) of 
the supernatant were taken for counting. 
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TABLE 4 
Assay protocol 
* nsb tube eca+ tube Bot tube 
Antiserum 0.02 ml 
Radio-tracer 0.02 ml 0.02 ml 0.02 ml 
Solubiliser 0.25 ml 0.25 ml 0.25 ml 
Tubes incubated at room temperature for 90 mln 
Dextran coated 
charcoal 
suspension 
0.1 ml 0.1 ml 
Tubes shaken at room temperature for 2.5 min 
Centrifuged at 9000g for 3 min 
Supernatants removed by aspiration 
Tubes with or without precipitates counted 
* nsb = non-specific binding 
+ eca = efficiency of charcoal adsorption 
t Bo = binding at zero dose. 
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Evaluation of magnetic charcoal as separating agent 
Materials 
Magnetic charcoal was prepared and used as previollsly 
described (AI-Dujaili et ale 1979). 
Method 
As described in previous section with magnetic charcoal 
replacing dextran-coated charcoal. 
Evaluation of separation methods (various) 
Materials 
The following lists some of the separating reagents 
tested. 
(a) Florisil Harman et ale (1980), 200-300 mesh (BDH) 
(b) Sephadex GIO and G25 (Pharmacia (GB) Ltd., 
Hounslow, Middx.) 
(c) Ammonium sulphate solution (saturated) 
(d) Second antibody; donkey anti-sheep, (Wellcome 
Foundation, Crewe, Cheshire and Guildhay 
Antisera). 
(e) Solid phase second antibody; donkey anti-sheep 
(Miles Labs Ltd., Slough, Berks and Bio Rad, 
Watford, Herts and ALT, Tunbridge Wells, Kent) 
and donkey anti-goat (Bio Rad). 
Method 
The protocol was as previously reported (Law and Moffat 
1980) except that the major proportion of the methanol was 
omitted to allow solubilisation with FC134. Separating 
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reagents were used as previously described in the 
literature, or in accordance with manufacturers 
instructions. 
Evaluation of polyethylene glycol (PEG) separation method 
Materials 
PEG (mol. wt 6000, Sigma) was dissolved in distilled 
water (20-35% w/v) with 0.1% sodium azide. Buffers were 
O.lM phosphate pH 7.4, and O.lM barbitone pH 8.6, containing 
FC134 (0.025% w/v) and bovine gamma globulins (BGG) Cohn 
fraction II (0-0.5% w/v) to act as carrier, and a universal 
phosphate/citrate/barbitone buffer, pH 4.2, 7.0 and 9.2 
containing FC134 (0.025% w/v) and BGG (0.2% w/v). 
Emit antiserum was obtained as part of a Syva 
Emit-d.a.u. kit for cannabinoid detection in urine (Syva UK 
Ltd, Maidenhead, Berks). 
Synthetic urine, prepared according to Rodgers et ale 
(1978) contained; urea 22 g, Na2HP04.2H20 1.8 g, NaCl 8.25 g, 
KCl 5.2 g, NaN3 1 g and creatinine 1.5 g in 11 of water. 
Method 
Experiments were carried out using the following 
protocol. 
Antiserum (Emit) diluted ca. 1/150 in buffer 0.1 ml 
ml Radiotracer ca 15 Kcpm/O.l ml in buffer 
Aqueous methanol (70% v/v) 
Synthetic urine 
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0.1 
0.05 ml 
0.05 ml 
The reagents were then incubated at room temperature 
for 60-120 min. PEG solution (0.3 - 1.0 ml) was added, the 
solutions vortexed, incubated (ca. 3 min), and centrifuged 
(4 min at 14000 xg). Supernatants were removed by 
aspiration and the precipitates counted. 
Investigation of matrix effects 
Materials 
Buffers, prepared at various pHs, contained BGG (0.2% 
w/ v ) and either FC134 (0.025% w/v), FC128 (0.025% w/v) or 
Triton X-405 (0.1% w/v). 
Anilinonaphthalene sulphonic acid (ANS) (Aldrich) was 
added to assay buffer to give a final concentration in the 
assay solution of 25-250 ~g tube. Adsorbants for serum 
pretreatment were kaolin (BDH), Norit A charcoal (Sigma) and 
silica gel (BDH). Lipase enzymes from various animal and 
plant species were obtained from Sigma. 
Method 
Experiments were carried out using the following 
protocol: 
Antiserum (Emit and Guildhay) in buffer 0.1 ml 
Radiotracer ca. 15 Kcpm/O.l ml in buffer 0.1 ml 
*Samples 0.02-0.05 ml 
*These were either aqueous (urine, synthetic urine) 
plasma or serum (treated and untreated) and aqueous methanol 
solutions of 6 8-THC-ll-oic acid, added alone or in 
combination. 
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The mixed reagents were incubated at room temperature 
for 60-120 min before the addition of PEG solution (27.5% 
w/ v , 0.5 ml). The solutions were then vortexed, incubated 
at room temperature and centrifuged. Precipitates were 
counted after aspiration of supernatants. 
Evaluation of cannabinoid RIA for routine detection of 
cannabinoids In body fluids 
Materials 
Bovine serum albumin (BSA), 35% solution (Sigma) or 30% 
solution (Lorne) were used in the preparation of the pH 5.75 
assay buffer; Na2HP042H20 52.5 g, citric acid monohydrate 
21.5 g per 2.51 distilled water containing NaN3 (O.l% w/v), 
BGG (0.2% w/v) and BSA (1.5% w/v). 
Assay standards were ~8-THC-ll-oic acid, 0, I, 2, 4, 8, 
16, 32 and 64 ng/ml in aqueous methanol (82.5% v/v) and the 
separation reagent was aqueous PEG (27.5% w/v) containing 
NaN3 (0.1% w/v). 
Control negative blood and urine samples were obtained 
from persons with no experience of cannabis use. 
Method 
Urine samples were assayed directly and after dilution 
with synthetic urine xlO and xlOO. Serum, plasma or the 
supernatant from centrifuged haemolysed blood was extracted 
by vortexing with 4 volumes of methanol for 30 s. After 
standing for 15 min the mixture was centrifuged and the 
methanolic supernatant assayed directly and after dilution 
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with 82.5% v/v aqueous methanol xlO. Analyses were carried 
out in duplicate sets of polypropylene microcentrifuge tubes 
(1.5 ml). The assay reagents were added in the following 
order: 
(i) Standard solution or methanolic serum extract or 
aqueous methanol (82.5% v/v) (20 ~l) 
(ii) Urine sample or synthetic urine (20 ~l) 
(iii) Radiotracer (100 ~l) diluted in assay buffer to 
give ca. 20 kcpm/lOO ~l (ca. 5 pg) 
(iv) Antiserum (100 ~l). Emit antiserum diluted 
1/140 in assay buffer. 
Non specific binding tubes contained assay buffer 
(100 ~l) in place of antiserum. 
The reagents were mixed by vortexing and incubated at 
room temperature for at least 75 min. PEG solution (0.5 ml) 
was then added and the solution again vortexed until 
homogeneous. After centrifugation (4.5 mln at 9000 xg), the 
supernatants were removed by aspiration and the precipitates 
counted in a gamma-counter. 
Data were processed by a PET computer runnJng the 
'Amersham ' curve fitting routine (Wilkins et ale 1977). 
This method of RIA data handling which utilises a four 
parameter least-squares iterative fit has been found to give 
excellent correlation with manual fitting routines 
(K. Pocock and P.A. Mason 1981, unpublished results). 
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Relative reactivity of ~9-THC-ll-oic acid-O-ester 
glucuronide 
Materials 
S-Glucuronidase (bovine, Type Bl), phenolphthalein 
glucuronide and lactoperoxidase were obtained from Sigma 
Chemical Co. ~9-THC-ll-oic acid glucuronide (ca. 120 ng/ml) 
was in 82.5% aqueous methanol pH 1.95, obtained following 
HPLC/RIA analysis of a urine sample from a person known to 
have used cannabis (See Chapter 4 and 5). 
Method 
An aliquot of the glucuronide solution was dried down 
under nitrogen «400 C), and the residue dissolved in O.OSM 
phosphate buffer (pH 5), containing either 8-g1ucuronidase 
or the control protein lactoperoxidase (50 ~l, 20 mg/ml). To 
each solution was added phenolphthalein glucuronide 
solution in water (1 ~l, 10 mg/ml). The test and control 
samples were treated in duplicate. After incubation at 370 C 
for 16 hr, an aliquot (1 ~l) of each reaction was checked 
with M sodium hydroxide solution to test for enzymic 
hydrolysis of the phenophthalein conjugate. The four 
solutions were treated with 3 volumes of methanol, vortexed 
then centrifuged to remove protein. The lactoperoxidase 
treated samples containing unchanged glucuronide, and the 
test samples containing ~9-THC-ll-oic acid were then 
analysed by RIA and the reactivity of the solutions 
compared. 
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A second aliquot of HPLC eluate containing the 
glucuronide was doubly diluted in 82.5% aqueous methanol, 
and the dilutions analysed by RIA and checked for 
parallelism with the ~8-THC-ll-oic acid standard curve. 
Comparison of RIA with Emit 
Materials 
Emit-d.a.u. urine cannabinoid assay reagents were 
obtained from Syva (UK) Ltd. Analyses were carried out 
using a Stasar III spectrophotometer and automatic 
pipetter/diluter (Gilford Instruments, Teddington, Middx). 
Method 
Y Twenty-four urine sampl ~ from the control experiment 
(see Chapter 5) were analysed by the RIA method and also 
using the Emit-d.a.u. urine cannabinoid assay according to 
the manufacturer's instructions. The samples were selected 
to contain a relatively wide range of cannabinoid levels, 
4-600 ng/ml (by RIA). Samples were diluted in synthetic 
urine to give an on scale result in both assays. 
RESULTS AND DISCUSSION 
Solubilisation of radiotracer in aqueous media 
A number of solubilisers including some not previously 
examined in RIA, were initially evaluated for their ability 
to solubilise the radiotracer in aqueous solution (Table 5). 
The effectiveness of a number of these compounds is 
shown ln Figures 15 and 16. With the exception of BSA, the 
other proteins, BGG, gelatin and the pseudo-protein PVP were 
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TABLE 5 
Compounds examined for their ability to solubilise 
the radiotracer in aqueous solution 
Compound 
Methanol 
Bovine serum alubmin (BSA) 
Bovine gamma globulin (BGG) 
Gelatin 
Polyvinyl pyrollidone (PVP) 
mol. wt. 10,000 and 40,000 
Sodium dodecyl sulphate 
Hexadecylammonium bromide 
(cetrimide) 
Triton X-405 
Triton X-305 
Tween 85 
Fluorad FC134 
Fluorad FC128 
Cremophor EL 
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Chemical type 
Polar organic solvent 
Serum protein 
Serum protein 
Animal protein 
Synthetic pseudo 
protein 
Anionic detergent 
Cationic detergent 
Nonionic polyoxyethylene 
detergent 
\I \I 
Nonionic polysorbate 
Cationic flurocarbon 
detergent 
Anionic flurocarbon 
detergent 
Ethylene oxide treated 
castor oil 
50 
Cremophor EL 
.02 . 1 .5 .02 
50 
Cetrimide 
Tween 85 
. 1 
Sodium 
dodecyl 
sulphate 
.5 .001 
FC 134 
.01 . 1 
Triton 
X 405 
O-r-----r------,-
.02 . 1 .5 .02 . 1 .5 .02 . 1 .5 
Figure 15. The effect of various detergents on the binding 
of radiotracer to polypropylene assay tubes. Vertical axis; 
percentage of radiotracer bound to the assay tubes. 
Horizontal axis; concentration of detergent (% w/ v for 
solids and % v/v for liquids). 
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80 
BGG 
PVP-40 Gelatine 
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.25 
30 
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BSA 
RIA grade 
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preparation 
O~------T---------~~ 
.5 1 2 4 
2 10 . 1 .5 1.75 
100 
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o 50 100 
Figure 16. The effect of various non-detergent solubilisers 
on the binding of radiotracer to polypropylene assay tubes. 
Vertical axis; percentage of radiotracer bound to the tubes, 
horizontal axis; concentration of solubiliser (% w/ v for 
solids and % v/v for liquids). 
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relatively ineffective at solubilising the tracer. BSA 
proved effective, although the magnitude varied with 4 
types of BSA studied. However, neither fatty-acid 
free or RIA grade were significantly better than crude 
preparations. All detergents tested were highly effective 
solubilisers although the degree varied markedly with 
concentration. The two Triton type detergents which had 
previously found use in RIA (Teale et al. 1975; Albro et a1. 
1979) were the least effective. Methanol caused virtually 
zero binding to the plastic tubes although the effect 
dropped off rapidly below 50% v/v. 
To examine the effect of the assay tube, polypropylene 
tubes from four manufacturers were evaluated and compared 
with polystyrene tubes, and soda glass tubes both untreated 
and silanised. The effect of the tube type was investigated 
in combination with three solubilising agents viz. BSA, 
FC134 and methanol. Although the absolute level of binding 
to the tubes varied with the solubilising agent, the 
relative merits of the tubes were the same with each agent. 
Binding to the tube decreased in the order: 
polystyrene > silanised glass > glass> polypropylene 
The difference between the best and worst was 15% of the 
tracer added. The slightly greater binding shown by 
silanised glass compared with untreated glass was in 
contradiction to data reported by Garrett and Hunt (1974) 
and the general practice of silanising glassware to prevent 
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drug losses through adsorption; especially in the field of 
cannabinoid determina~ions. However this result is in 
general agreement with more recently published data 
(Mizutani 1982) which suggests that a wide range of drugs 
and antibiotics bind more highly to silanised glass than 
untreated glass. 
The extent of binding to the polypropylene tubes also 
showed an unexpected variation, not only between tubes from 
different manufacturers, but also between batches from one 
manufacturer. One particular batch of tubes (Hughes and 
Hughes) gave levels of binding which were ~8% lower than all 
other tubes studied. This particular batch of tubes also 
exhibited significantly different surface characteristics, 
being much more wettable than the other tubes. When 
contacted, the suppliers stated that different batches 
of polypropylene were used with different sets of moulding 
equipment. They were unable to state what the differences 
were between the batches of polypropylene or how they could 
relate to the present problem. 
Washing of assay tubes with methanol, ethyl acetate and 
hexane was tried in an attempt to remove possible mould 
release agents which may have been dissolving the tracer at 
the tube interface. No improvement after washing was 
observed and in most instances the level of non specific 
binding actually increased. 
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It is recommended that all tubes used for the RIA of 
lipophilic compounds be examined and tested for their degree 
of binding of tracer. All further data presented here were 
obtained using tubes showing low non-specific binding. 
The effect of the presence of solubilisers on antibody 
binding of radiotracer 
Those solubilisers showing the greatest efficacy in the 
previous experiments were evaluated under normal assay 
conditions (i.e. in the presence of antiserum), and compared 
with previously used solubilising agents, Triton X-405 and 
methanol. 
The assay procedure employing charcoal as separating 
agents was as previously described (Law and Moffat 1980). 
Three parameters were investigated, viz. non-specific binding 
to the plastic tubes (nsb), efficiency of charcoal 
adsorption in the absence of antibody (eca), and binding of 
tracer to antibody at zero dose (Bo). 
The results of these experiments are given in Table 6. 
The levels of non-specific binding showed a wide variation 
from 3% (Cetrimide, Tween) up to 40% (methanol), although 
the variation in the adsorption efficiency of the charcoal 
(eca) was much less. The most important factor in regard to 
the basic working of the immunoassay was the very large 
variation in Bo from 0% (cetrimide) to 65% (FCI34). From 
this and other experiments it appeared that the ability of 
the antibody to bind the antigen could be severely reduced 
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TABLE 6 
The effect of various solubilisers on three assay 
parameters; non specific binding (nsb), efficiency of 
charcoal adsorption (eca) and binding at zero dose (Bo) 
Solubiliser and % conc.+ 
% of total cpm 
added 
% of corrected 
total* 
nsb eca=t Bo-eca Bo-eca 
Cremephor EL 
Tween 85 
(0.01) 
(0.01) 
Hexadecylammonium (0.01) 
bromide(cetrimide) 
Sodium dodecyl 
sulphate 
Triton X-405 
Triton X-305 
FC134 
FC128 
BSA 
Methanol 
( 0 . 1 ) 
(0.5) 
(0.5) 
(0.01) 
(0.01) 
( 1. 0 ) 
(25) 
5 
3 
3 
2 
2 
2 
10 
23 
14 
40 
8 55 
12 50 
18 o 
7 6 
7 41 
5 46 
12 60 
20 50 
12 58 
10 30 
*Total counts corrected for counts lost through 
non-specific binding i.e. total corrected = total 
counts - nsb counts 
+All concentrations are w/v except the methanol 
solution which is v/v 
~Figures represent the proportion of tracer not 
adsorbed 
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58 
52 
o 
6 
42 
47 
67 
65 
67 
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by the presence of detergents or other binding agents e.g. 
BSA or assay tubes. In the presence of the detergent the 
antigen will probably be solubilised by entrapment in a 
micelle. Thus the level of binding will be related to the 
ease with which the antibody can penetrate the micelle. The 
degree of penetration and hence level of binding appeared to 
be related to the chemical nature of the detergent. The 
detergents will also bind to the surface of the antibody, 
possibly denaturing it and reducing its binding power. From 
these experiments, binding was observed to decrease down the 
following series with given detergent type: 
ionic 
fluorocarbon > 
nonionic 
hydrocarbon > 
ionic 
hydrocarbon 
For each new assay it is obviously necessary to select 
carefully and optimise the solubiliser concentration to give 
maximum specific binding with minimum non specific binding, 
although ionic halocarbon detergents would appear to be 
first choice for such studies. 
The choice of best solubiliser for the cannabinoid RIA 
lay between BSA and FCl34 (Table 6) both of which gave 
similar results. However, BSA has been shown to have 
variable and unreliable chemical composition resulting in 
variable specific and non-specific binding in the RIA of 
~9-THC (Cook et al. 1976). BSA has also been shown to cause 
interference in a number of other RIAs e.g. T-3 and insulin 
(Shearer et al. 1978). Because of these problems FCl34 was 
considered more suitable for further study. This work 
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indicated that a concentration of 0.0167% w/ v in the assay 
medium (0.025% w/ v in the diluent buffer) to be optimal for 
maximum specific binding and minimum non-specific binding 
(ca. 10%). This solubiliser was then employed in an assay 
to determine the best method of effecting separation of 
bound and free antigen. 
Evaluation of RIA separation methods 
Magnetic charcoal (AI-Dujaili et al. 1979) was examined 
as an alternative to the normal dextran coated charcoal for 
separation of bound and free antigen. This material, 
consisting of charcoal entrapped along with iron particles 
in a polyacrylamide gel, was reported to have lower activity 
than normal coated or uncoated material, making contact time 
less critical. A further advantage of this form of charcoal 
was that it avoided the need to centrifuge. Precipitation 
was brought about by placing a strong magnet under the assay 
tubes. When prepared according to Al-Dujaili et al 
(1979) however, magnetic charcoal showed higher activity 
than expected and a similar critical time dependence as 
dextran coated charcoal. 
Florisil which has been recommended as an alternative 
to charcoal in the assay of testosterone (Harman et al. 
1980) was found to be relatively efficient at adsorbing 
tracer from solution. However, its ability to strip antigen 
from antibody was as great if not greater than that of 
charcoal, making it unsuitable for use. 
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Sephadex GIO and G25 were similarly investigated Slnce 
they have the ability to absorb/entrap small molecules (Mol 
wt <700 and 1000-5000 respectively). Neither were found to 
be particularly efficient at absorbing tracer from solution. 
Separation by the addition of an equal volume of 
saturated ammonium sulphate solution is one of the simplest 
and relatively efficient fractional precipitation methods, 
although often resulting in high non-specific binding. This 
technique has been effectively employed in a number of 
commercial drug RIAs (Roche Abuscreen) for morphine, 
barbiturates, cocaine and amphetamine. However when tested 
1n cannabinoid assay in the presence of the detergent FC134 
no precipitate was produced after centrifugation. The 
. 
cloudy nature of the solution suggested that the globulin 
fraction in the antiserum and the carrier protein (0.2% w/v 
BGG in assay buffer) had been denatured but were being held 
1n solution by the solubilising action of the detergent. 
When tested with one particular batch of BSA as 
solubiliser, ammonium sulphate separation gave a simple and 
sensitive assay with relatively high binding and low 
non-specific binding. However, it was impossible to 
reproduce this assay with BSA from the same, or a number of 
other manufacturers and the original experiments were 
considered uncharacteristic and this line of research was 
discontinued. 
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A number of commercial second antibody preparations, 
both as liquid sera and bound to solid matrices were 
investigated. These were generally found to give lower 
binding than a comparable assay using charcoal and in 
certain instances unacceptably high non-specific binding 
(~15%). The non-specific binding to the solid phase second 
antibody reagents could be reduced somewhat by washing the 
precipitate with FC134 solution (0.0167% w/v) although the 
final level of non-specific binding was still relatively 
high (ca. 10%). The extra stages involved in the washing 
procedure, and the need to continuously agitate the assay 
mixture to prevent settling of the solid phase reagent made 
this approach unattractive. Dilution of the assay mixture 
with the FC134 solution (0.025% w/v) prior to centrifugation 
did not reduce non-specific binding indicating that the 
tracer was bound to, rather than entrapped in the 
precipitate. 
In the evaluation of PEG for separation of bound and 
free antigen, a number of factors were investigated, 
initially using the recommended concentration of 12.5% w/v 
PEG in the final assay mixture. Phosphate and barbitone 
buffers were compared for their effects on binding at zero 
dose and 100 ng/ml b 8-THC-ll-oic acid and on non-specific 
binding. Although barbitone buffer had been previously 
shown to be superior to phosphate (Sourgens et al. 1979), 
no significant differences were observed between the two 
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buffer systems over the molarity range 0.01 mol/l to 0.05 
mol/I. The efficiency of separation was also found to be 
relatively constant across the pH range 4.2-9.2. A control 
experiment using dextran coated charcoal separation was 
carried out to isolate any potential effects of pH on PEG. 
By varying the concentration and volume of PEG added, 
initial experiments suggested that adding 3.3 times the 
volume of 25% w/v PEG could reduce non-specific binding by 
2-3%. A more systematic study indicated that increasing the 
volume or concentration of PEG added not only reduced 
non-specific binding, but had a significant effect on 
specific binding. Figure 17 shows the effect on binding of 
adding an increasing concentration of PEG at a 1:1 and 1:3.3 
ratio of assay medium to PEG solution. The apparent maximum 
in binding with the excess of PEG solution (l ml added) was 
probably due to incomplete precipitation in the large volume 
of a viscous medium. This separation was incomplete despite 
the high centrifugal force (9,000 xg for 4.0 min). Using an 
equal volume of PEG solution, specific binding rose 
gradually to a maximum with ca. 18% w/v final PEG 
concentration. Further experiments confirmed this result, 
and separation was found to be conveniently effected by 
adding 0.5 ml of PEG solution (27.5% w/v) giving a final 
concentration of 17.2% w/v. Thus by increasing the final 
PEG concentration from that normally recommended, specific 
binding could be increased by ca. 10% overall. These 
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Figure 17. The effect of volume (0.3 ml (.) and 1 ml (A) ), 
and concentration of PEG solution on specific and 
non-specific binding in the RIA. The abscissa shows the 
concentration of PEG solution used (a), and the final 
concentration in the assay medium after adding 1 ml (b) and 
3 ml (c). 
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results further emphasise the statement made by Desbuquois 
and Aurbach (1971) that the conditions for optimum 
separation in any new assay should be carefully 
investigated. Under these conditions the PEG separation 
method gave comparable binding to separation by dextran 
coated charcoal. The calibration curves using the two 
separation methods showed similar shape with dextran coated 
charcoal giving only slightly greater sensitivity, due to 
the increased slope. 
Matrix effects 
In previous cannabinoid RIAs used and developed in this 
laboratory (\villiams et al. 1978 and 1979, Law and Moffat 
1980 and Law et al. 1981), methanol was the primary 
solubiliser. This was introduced into the assay by 
preparing the 3H-tracer and standards in an aqueous methanol 
solution (40-70% v/v). Samples analysed were either aqueous 
urlne, or methanolic extracts of serum* or plasma. 
To minimise matrix effects and maintain a constant 
methanol concentration, urine analyses required the addition 
of a methanolic solution, and analysis of standards or blood 
extracts required addition of an aqueous buffer solution. 
This extra addition, which varied with sample type, increased 
the general complexity of the assay. Since the assay under 
development was independent of methanol as solubiliser and 
*Por the purposes of this discussion serum is defined as the 
supernatant from centrifuged whole blood. The blood can be 
freshly taken or haemolysed and/or putrefying. 
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the small sample size (20-50 ~l) suggested that matrix 
effects may have been minimal, direct addition of different 
sample types was examined. Initially, extraction of serum 
with methanol (Williams et al. 1978) was omitted and samples 
were added directly to the assay tubes. At zero doses this 
resulted in increased binding (5-10%) over comparable 
methanolic standards, presumably due to the blood proteins 
acting as a non-specific binding agent. The effect was 
found to be more pronounced when a full standard curve was 
examined with a marked deviation between the two curves at 
high dose (Figure 18). This effect resulted in gross 
underestimation of blood cannabinoid levels. To reduce any 
possible non-specific protein binding, anilinonaphthalene 
sulphonic acid (ANS) was added to each tube at a 
concentration of 25-250 ~g/tube. ANS has been used 
previously to reduce binding to circulating natural binding 
proteins in the RIA of endogenous biological materials e.g. 
cortisol (Brock et al. 1978). In this study no improvement 
was observed. At the lowest concentration studied (25 
~g/tube), a small reduction in the difference between the 
methanolic standard and serum generated curves was observed 
Figure 18. Increasing the ANS concentration however, 
reduced binding at zero dose considerably with little effect 
on binding at 100 ng/ml ~8-THC-ll-oic acid. This resulted 
~n a near horizontal curve at the ca. 45% bound level. 
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Figure 18. The effect on a standard curve of serum (_), 
serum diluted 1:1 in synthetic urine containing ANS, 25 ~g 
(0) and 250 ~g (4), 20 ~l of each. A typical standard curve 
is also shown (e). 
Previous experience in regard to the problems caused by 
the lipophilic nature of cannabinoids and their extensive 
protein binding, along with results of this experiment, 
suggested direct addition of serum (or plasma) to the assay 
could not be easily attained. This approach was 
consequently discontinued. 
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Repeat experiments were carried out using methanolic 
serum extracts in place of serum. Figure 19 shows the 
effect on binding of adding methanol serum extracts, 
80~ 
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b8 -THC-11-oic acid (ng/ml) 
Figure 19. The effect on the standard curve of methanol 
serum extract (0), methanol plasma extract (.) and blank 
pooled urine (A), 0.025 rnl of each. A typical standard curve 
is also shown (.). 
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methanol plasma extracts and blank pooled urine compared 
with standards prepared in aqueous methanol (70% w/ v ). 
Although blank pooled urine and synthetic urine (data not 
shown) gave similar curves they were different from 
standards in methanolic solution. The extracts of serum and 
plasma showed even greater divergence from the typical 
standard curve. 
This experiment indicated that the various biological 
samples or sample extracts were not equivalent to one 
another or to the standard solutions. Thus, to eliminate 
these matrix effects, addition of an aqueous sample (urine, 
synthetic urine) must be accompanied by addition of a 
methanolic solution (70% v/v aqueous methanol or methanol 
serum extracts) and vice versa. Figure 20 shows the effect 
on a standard curve of adding various reagents/samples in 
pairs i.e. methanolic + aqueous. Blank pooled urine had 
the same effect on binding as synthetic urine with the 
curves almost superimposable. Thus urine samples could be 
accurately read off against a standard curve generated with 
synthetic urine. The methanol serum and plasma extracts 
although containing ca. 70%V/v methanol showed marked 
differences in binding from the standard curve prepared 1rl 
70% v/v methanol. Although binding at zero dose was less 
than that for 70% v/v methanol solutions the overall effect 
of the blood extracts on binding was similar to, although 
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j18-THC-11-oic acid (ng/ml) 
Figure 20. The effect on a standard curve of adding varlOUS 
paired sample combinations. Methanol serum extract/ 
synthetic urine (0), methanol plasma extract/synthetic 
urine (.), methanol 70% V/v/blank pooled urine (&) and a 
typical standard curve prepared from aqueous methanol 
(70% v/v)/synthetic urine (e). The same volume, 0.020 ml of 
each reagent was used. 
less marked, than that observed with direct addition of 
serum (Figure 18). The cause of this phenomenon was 
considered to be some co-extracted material interacting 
with the cannabinoids in some way to alter the level of 
binding, although the differential effect across the curve 
was difficult to rationalise. 
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The phenomenon was independent of antiserum Slnce 
it was observed with both Emit and Guildhay antisera. The 
l25I-tracer had also been eliminated as the cause of the 
problem as a similar effect had been previously observed 
using [G_3HJ-~9_THe as radiotracer (Law et ale 1980). 
To eliminate possible carryover of interfering small 
proteins through incomplete denaturation or precipitation 
the following modifications to the extraction procedure were 
evaluated: 
(a) heating the methanolic extracts to 900 e for 5 
min prior to analysis 
(b) carrying out the methanol extraction after 
acidification or basification of the serum or 
plasma sample 
(c) extraction of the serum with ether, and after 
evaporation of the organic phase, reconstitution 
in 70% aqueous methanol for analysis. 
These methods of pretreatment or extraction provided no 
solution to the problem which in a number of instances was 
considerably aggravated. The lack of success in part (c) 
was strong evidence that proteinaceous material was not an 
interfering factor. 
To eliminate possible interaction of natural blood 
lipids with the cannabinoids or cannabinoid/detergent 
complexes various forms of pretreatment were tested. 
Incubation of plasma with various lipase enzymes prior to 
extraction was found to have little effect. Similarly, 
treatment of both serum and plasma with solid adsorbants 
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(charcoal, silica gel and kaolin) was also without effect. 
Even if it had proved successful, this latter experiment was 
not considered a practical solution. The adsorption of any 
small molecular weight interferent would be expected to be 
accompanied by similar adsorption of cannabinoid compounds. 
Although these experiments failed to shed light on the 
cause of the problem, by a process of elimination the 
detergent solubiliser began to emerge as a possible indirect 
source of the phenomenon. However the type of detergent 
(i.e. cationic, non ionic and anionic, with FC134, Triton 
X-405 and FC128 as the test substances) was found to be 
immaterial. As an offshoot of this experiment it was noted 
that pH of the assay buffer had a pronounced effect on the 
shape of the methanol serum extract curve and its position 
relative to a normal standard curve (Figure 21). In acid 
solution (pH 4) the curve generated using a methanol serum 
extract was above the 70% w/v methanol curve, thus leading 
to underestimation of blood cannabinoid concentrations. As 
the pH of the assay medium was increased, the shape of the 
extract curve changed, such that the two curves crossed at 
high concentration with the extract curve essentially below 
the standard curve. Further experiments indicated that at 
pH 5.75 the difference between the two curves was minimal, 
with the biggest difference in terms of concentration at any 
one point being a factor of 1.8. Thus using this assay 
procedure, quantification of cannabinoids in blood could be 
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Figure 21. The effect of assay buffer pH on the binding of 
~8-THC-ll-oic acio standards. Standards prepared in 
methanol serum extract at pH 4 (_), and pH 7.4 (.) and 
70% v/v aqueous methanol at pH 4 or 7.4 (e). 
effected with a reasonable degree of accuracy. Thus the 
effect of pH was found to be an important factor in reducing 
the problem of matrix effects although it was impossible to 
rationalise this mechanistically in terms of the various 
assay constituents and the results of previous experiments. 
One point of note was that the pH of minimal curve 
difference (pH 5.75) coincided with the pKa of the residual 
basic function on the iodohistamine moiety of the 
radiotracer. Whether or not this was a coincidence or a 
pointer to the underlying cause of the problem could not be 
deduced. 
Because of time constraints, the shortcomings of the 
assay in regard to quantification of cannabinoids in blood 
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samples were accepted. High accuracy was not considered a 
major prerequisite for a general screening assay, providing 
the difference between positive and negative results could 
be easily assessed. 
During a full evaluation of the assay, non-specific 
binding levels were found to be high and variable. A number 
of factors were investigated and the main problem was found 
to lie with the working solution of radiotracer in assay 
buffer. Increasing the length of time for which the working 
solution had been prepared caused significant increases in 
non-specific binding (Table 7). 
TABLE 7 
The effect of the age of working solutions of radio-tracer 
on non-specific binding in the RIA. Solubilant FC134, 
separation method PEG, carrier protein EGG 
Age of radio-tracer non-specific binding 
solution % of total counts 
10 min 9.3 
2 hr 8.8 
1 day 11.4 
2 day 12.5 
3 day 14.0 
The exact reasons for this were unclear. However 
interaction of the radiotracer with BGG and detergent on 
standing may have resulted in irreversible binding to the 
protein component leading to higher non-specific binding. 
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A further casual observation indicated that the s1ze of 
the assay, i.e. the number of tubes, was related to the 
level of non-specific binding. Small assays (ca. 10 tubes) 
gave ca. 8% non-specific binding where larger assays (~50 
tubes) gave much higher levels (12-15% non-specific binding). 
The cause of this was traced to the type of pipettes used 
for dispensing the reagent solutions. In small assays, 
standard "one shot" Finn or Oxford type pipettes were used. 
In the larger assays a repeating Eppendorff Multipette was 
employed. The multipette utilises a syringe which stores 
the liquid to be dispensed. This liquid is introduced into 
or ejected from the syringe/pipette by raising or depressing 
a plunger. This action creates a tremendous force as the 
sample passes through a narrow orifice of the syringe when 
fitted with a standard pipette tip. The shearing forces 
created in the act of filling or flushing the syringe 
could have altered the physiochemical properties of the 
solution through cleavage or disruption of the micelles, 
thus leading to reduced solubility of the tracer and hence 
the greater non-specific binding to plastic tubes observed 
experimentally. 
Despite these factors being eliminated from subsequent 
assays, non-specific binding still remained high and 
variable. Experience suggested that although detergents 
were highly effective solubilisers for RIA, they produced 
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complex and unpredictable assay systems. The assay 
evaluation was abandoned and BSA was further examined as a 
solubiliser. 
Utilising the optimal conditions and reagent 
concentrations previously determined, the concentration of 
BSA giving maximal binding and minimal non-specific binding 
(~lO%) was found to be 1.25% w/v in the assay solution. 
Several batches of BSA preparations from two manufacturers 
were investigated for their effect on binding, specific and 
non-specific. At a concentration of 1.5% w/v in assay 
buffer (1.25% final concentration) little difference was 
observed between the BSA preparations studied with PEG, 
contrary to the results obtained with ammonium sulphate 
separation. Preliminary experiments indicated the assay to 
be robust with relatively constant levels of binding and 
non-specific binding, a full evaulation was undertaken the 
results of which are presented in the following section. 
Evaluation of cannabinoid RIA 
Selection of antiserum 
At the onset of this work the intention was to use the 
broadly specific Guildhay cannabinoid antiserum (Lot No. 
133Y/22/S) which had been successfully used in previous RIA 
methods in this laboratory. The manufacturer's stock of this 
antiserum at this point in the assay development was too 
low, however, to provide sufficient material for use by 
several laboratories, over a number of years. Newly raised 
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antisera from the same commercial source was found to gIve 
much lower titres. Attention was therefore turned to the 
Emit antiserum, which was one of two reagents in the Syva 
Emit-d.a.u. kit for cannabinoid detection. The 
cross-reactivities for the major metabolites with this 
antiserum were similar to,those with the Guildhay antiserum. 
Used at a diluton of 1/140 the cost was approximately Ip per 
test. Examination of the protein content suggested that the 
working dilution was equivalent to a dilution of the 
original serum of the order of 1/9000, making it more suited 
to any further work on solid phase second antibody 
separations as part of an automated procedure at a future 
date. 
Variation of binding with time 
The variation in specific and non-specific binding with 
increasing incubation time is shown in Figure 22. Specific 
binding was seen to plateau at ca. 3 hr although between 
1.5-3 hr the increase in binding was slow. An incubation 
time of ~ 75 min was found to be convenient giving an 
acceptable level of binding. Analyses carried out with 
incubation times of 70 min or 6 hr gave no significant 
differences in levels of cannabinoids from known positive 
samples. 
Non-specific binding was constant between 10 mln and 8 
hr although both this and specific binding increased 
significantly when incubation time was extended to 24 hr. 
94 
60 
%Bound 
40 
20 
.. 
• 
• 
• 
.. 
• 
.. 
o~~~~ __ ~ __ ~ __ ~~ __ ~ __ ~~ 
o 2 4 6 8 '24 
Incubation time (hr) 
Figure 22. The effect of increasing incubation time on 
binding, at two doses zero (e), 2 ng/ml ~8-THC-ll-oic acid 
(.) and non-specific binding (4). 
Variation in binding with PEG contact time 
Following the addition of PEG and thorough mixing by 
vortexing, both specific and non-specific binding were found 
to be constant for up to 18 hr prior to centrifugation and 
precipitation. Under normal assay conditions tubes were 
centrifuged immediately after mixing. 
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Stability of reagent working solutions 
Working solutions of antiserum and radiotracer were 
prepared in assay buffer and used for the analysis of known 
blank and positive samples over a period of 13 days. 
Compared with those freshly prepared, the old reagents gave 
no significant differences in binding (specific or 
non-specific), nor in background levels nor in the 
quantification of cannabinoids. Thus, in contrast to the 
similar assay using the detergent solubiliser, the present 
assay conditions allow working solutions of antiserum or 
tracer to be stored for at least 2 weeks without detriment 
to the performance of the assay. 
Cross-reactivity studies 
Table 8 lists the cannabinoids studied and their 
cross-reactivities relative to ~8-THC-ll-oic acid. The data 
given in parenthesis are those provided by Syva with early 
batches of Emit reagents. 
In general, the antiserum appeared relatively 
I 
insensitive to changes in the basic structure of THC at the 
9- or ll-positions and to a lesser extent the 8-position. 
The ~8-isomers appeared more reactive towards the antiserum 
than the corresponding ~9-isomers. These observations are 
in general agreement with the reported mode of production of 
the antiserum using an immunogen consisting of 11-oxo-~8-THC 
96 
TABLE B 
Cross reactivities of cannabinoids, their 
metabolites, and synthetic analogues 
Compound 
II-Hydroxy-~9_THC 
~B-THC-Il-oic acid 
~9-THC-ll-oic acid glucuronide 
~9-THC-Il-oic acid 
Ba,II-Dihydroxy-~9_THC 
Ba-Hydroxy-~9_THC 
B8-Hydroxy-~9_THC 
~9-THC 
Il-Hydroxy-cannabinol 
~B-THC-ll-oic acid-2-Iodohistamide 
Cannabinol-ll-oic acid 
Cannabinol 
51-Hydroxy-~9-THC 
l'-Hydroxy-~9_THC 
l"-Oxo-cannabinol 
Cannabidiol 
51-Carboxy-~B_THC 
Levonantradol 
Nabilone 
Relative 
0.9 
1.0 
1.1 
1.2 
1. 5 
1.5 
1.6 
2.B 
4.0 
4.7 
5.0 
30 
47 
200 
> 500 
> 500 
> 500 
> 500 
> 500 
> 500 
Reactivity 
(O.B) 
( 1 .0) 
( 3 . 1 ) 
( 1 . 7 ) 
( 2 . 9) 
( 1 • 7 ) 
(B.5) 
(62) 
*Relative reactivity is determined at 50% depression of 
binding equivalent to ca. B ng/ml ~B-THC-ll-oic acid 
Data in parenthesis are those provided by Syva with 
early batches of Emit reagents 
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* 
linked to BSA through the carbonyl group (Rodgers et al. 
1978). Modifications to the pyran ring as in cannabidiol, 
or the pentyl side chain resulted in dramatic loss of 
reactivity. It is interesting to note that aromatisation of 
the top ring to give the corresponding cannabinol compounds 
also results ln significant loss of reactivity. This 
pattern of antibody reactivity is a most useful feature 
considering the major metabolic pathways of ~9-THC in man 
(see Chapter 1). 
Analysis of ~9-THC-ll-oic acid glucuronide with and 
without glucuronidase treatment showed the conjugated form 
to be more highly cross-reacting, by a factor of 1.3 than 
the free ~9-acid itself. Analysis of serial dilutions of 
the glucuronide over the range 2-64ng/ml, showed this 
metabolite and the calibration standard ~8-THC-ll-oic acid to 
have parallel curves. Thus the 8-,9- and Il-substituted 
metabolites would be expected to cross react strongly in any 
assay utilising this antiserum. 
As expected, the synthetic cannabinoids Levonantradol(R) 
(Pfizer) and Nabilone(R) (Lilly), both of which possess major 
structural deviations from the basic cannabinoid nucleus, 
exhibited no cross-reactivity at the concentrations tested. 
~8-THC-ll-oic acid was selected as the assay standard 
despite a difference in reactivity between this and the 
naturally occurring ~9-isomer. The main reason for this was 
that ~8-THC-ll-oic acid is more readily available and more 
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easily synthesised than the corresponding 69-isomer. Also, 
since blood and urine samples contain up to four different 
detectable metabolites, (including ~9-THC-II-oic acid, see 
Chapter 4) of unknown reactivity, accurate assessment of 
body fluid cannabinoid concentration by direct RIA is most 
difficult. 
Figure 23 shows a typical standard curve obtained uS1ng 
~8-THC-ll-oic acid standards. The assay is seen to have 
good sensitivity (partially reflected in the small sample 
volume, 20 ~l) and a useful dynamic range. 
60 
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Figure 23. Typical assay calibration curve. 
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Assay cut-off levels 
The mean background level from 100 blank urine samples 
was found to be 0.32 ± 0.23 ng/ml (S.D.). A positive/ 
negative cut-off level of 2 ng/ml has been used to give 
>99.7% certainty of a true positive result. 
The mean background level from 55 blank blood samples 
was found to be 1.8 ± 2.5 ng/ml (S.D.). A positive/negative 
cut-off level of 10 ng/ml has been used to give a >99.7% 
certainty of a true positive result. 
The effect of sample additives 
The common inorganic preservatives, sodium fluoride/ 
phenylmercuric nitrate, sodium fluoride/sodium sulphate and 
sodium azide for urine and the preservative/anticoagulant 
sodium fluoride/potassium oxalate for blood were examined 
for their effect on background levels. At 2.5 times the 
recommended concentrations, no significant variations in 
background levels were observed. However, the results of 
previous work on preservatives for biological samples (Law 
and Moffat 1981) recommended the use of sodium azide as 
preservative. The relatively low active concentration of 
this compound (0.01%-0.1%) makes it more suitable when 
immunological tests are to be performed. 
Assay accuracy 
Notwithstanding the fact that it is difficult to apply 
the concept of accuracy to a broadly specific assay, 
analyses of blood and urine samples spiked with 
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~8-THC-ll-oic acid showed good recovery of cannabinoid 
material across a range of levels, (Table 9). 
TABLE 9 
Recovery from blood and urine samples spiked to 
various concentrations with ~8-THC-11-oic acid 
Correlation+ 
Concentration (ng/ml)* Slope Intercept 
coefficient 
Blood actual 7.5 35 110 205 
Blood found 6.0 35 100 185 0.997 1.12 -1.41 
Urine actual 1.5 6.9 22 41 
Urine found 1.1 6.6 21 48 0.984 0.87 2.17 
* The results represent the mean of three separate analyses 
+Obtained from the results of twelve separate analyses 
Assay reproducibility 
Samples of plasma, haemolysed blood and urine spiked 
with ~8-THC-ll-oic acid (3.8-100 ng/ml), gave good 
intra-assay coefficients of variation ranging from 3.2 to 
8.1% (n = 10) (Table 10). Similar samples assayed over a 
period of 40 days gave inter-assay coefficients of variation 
ranging from 24% (haemolysed blood, 7.3 ng/ml), down to 7.7% 
(urine, 7.1 ng/ml), (Table 11). 
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TABLE 10 
Assay reproducibility - intra-assay coefficients of variation 
f or plasma, haemolysed blood serum and urine 
Sample Mean level Standard Coefficient number of 
ng/ml deviation of variation analyses 
Plasma+ 10 0.81 8.1 12 
Haemolysed blood+ 12 0.71 5.9 12 
serum 
Plasma+ 103 4.4 4.3 12 
Haemolysed blood+ 98 4.0 4.1 12 
serum 
Urine* 3.8 0.18 4.6 20 
Urine* 7.6 0.47 6.1 10 
Urine* 22 0.70 3.2 9 
Urine* 33 2.3 6.8 10 
+Sample spiked with ~8-THC-11-oic acid 
*Sample spiked with differing amounts of urine containing a high level 
(ca. 20~g/ml) of cannabinoid metabolites 
Analytical precision was similar for plasma and 
haemolysed blood samples. 
The inter-assay coefficients of variation are somewhat 
higher than would be expected from consideration of the 
intra-assay variation, and indicate some day to day 
instability of the assay, which is comparable to that 
reported for a THe-specific RIA utilising a 125 1 tracer 
(Owens et ale 1981). This problem, however, does not oetract 
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TABLE 11 
Assay reproducibility - inter-assay coefficient of 
variation for urine and haemo1ysed blood serum 
Sample Mean 1eve1* Standard Coefficient number of deviation of variation analyses 
Urine 1.5 0.38 26 11 
7.1 0.55 7.7 11 
22 3.7 17 11 
47 5.4 12 11 
Serum 7.3 1.8 24 15 
39 5.8 15 17 
101 11 11 17 
187 28 15 17 
*Samp1es spiked with ~8-THC-11-oic acid 
from the general usefulness as accurate quantification of 
cannabinoids is not a prlme requirement of the assay. Also, 
interpretation of any quantitative result, apart from 
positive/ negative or low/high, is most difficult. 
Stability of cannabinoids in biological fluids 
O'Connor and Rejent (1981) recently reported variable 
and unpredictable decreases of Emit detectable cannabinoids 
in urine samples stored at -18o C. Similar observations with 
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RIA have occasionally been made in this laboratory with 
blood and urine and in another laboratory (R N Smith, 1982, 
personal communication) with blood samples. However, when 
urine samples containing a range of cannabinoid levels (ca. 
4-120 ng/ml) were stored at 40 C and -18o c in both soda glass 
(unsilanised) and polystyrene containers, no significant 
changes in cannabinoid levels were observed over a 3 month 
storage period. Experiments with plasma samples stored 
under identical conditions for 2.5 months gave similar 
results to urine. The absorption of cannabinoids by rubber 
septa has been suggested as a cause of apparent cannabinoid 
instability on storage. However a sample of plasma stored 
ln contact with a rubber septum showed no apparent decrease 
in cannabinoid activity over the same storage period. The 
samples investigated were only several days old prior to the 
start of the experiment. Although these control experiments 
have indicated relatively high cannabinoid stability in 
biological specimens, in contradiction with reported work 
(O'Connor and Rejent 1981), storage of samples at -18oc in 
glass containers is recommended. 
further in Chapter 5. 
Interpretation of assay results 
The problem is discussed 
A positive result from a blood or urine sample is 
consistent with the person, from whom the sample was obtained, 
having used a cannabis preparation. However, due regard 
should be given to the possibility of passive inhalation as 
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discussed in Chapter 6. Control experiments (see Chapter 5) 
indicated that positive results from blood samples can be 
obtained for up to 5 days following consumption of an 
average amount of cannabis (ca. 20 mg THC orally or 10mg 
smoked). Similarly, positive results may be obtained from 
urine for at least 10 days after consumption of cannabis. 
The important point to note is that even from blood 
analysis, positive results can be obtained long after the 
pharmacological action of ~9-THC has passed. 
Although the RIA is generally free from interference 
due to extraneous agents, false negative results have been 
obtained from urine samples containing blood proteins 
(R N Smith, 1982, personal communication). This is probably 
attributable to non-specific binding by such proteins, and 
is the reason why blood samples are extracted before RIA 
analysis. 
Compared with other broadly specific cannabinoid immuno-
assay TIlethods used and evaluated in this laboratory 
(Wiliams et ale 1978 and 1979, and Law et ale 1982) samples 
containing high levels of cannabinoids showed better 
agreement between the results from serial dilutions. This 
may indicate similarity in cross-reactivity between stan-
dards and cannabinoid metabolites or more probably parallel 
curves for standards and metabolites over the working assay 
range. 
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Comparison with the Emit-d.a.u. urine cannahinoid assay 
The Emit-d.a.u. assay is the only commercial kit for 
cannahinoid detection available in the UK. As this is 
likely to be used or quoted by defence experts or hospital 
analysts it was considered useful to compare this technique 
with the RIA. 
Despite differences 1n cross-reactivity data and assay 
tracers, as well as the semi-quantitative nature of the Emit 
assay the two methods were in good quantitative agreement, 
with the Emit assay giving slightly higher results. The 
correlation coefficient was 0.96, slope 0.88, and intercept 
4.8 ng/ml (n = 24). However, because of its high positive/ 
negative cut-off level 1.e. 20ng/ml ~9-THC-oic acid the Emit 
assay gave a number of false negative results compared with 
the RIA. 
CONCLUSION 
The RIA method described here has a useful dynamic 
range and shows good absolute sensitivity (ca. lng/ml), a 
factor which is partially reflected in the small sample 
volume required for analysis (60~1 of urine and 40~1 of 
serum or plasma, for duplicate determinations including 
serial dilutions). The assay is capable of detecting 
cannabinoids in blood or urine many days after consumption 
of cannabis. The use of a l25I-radiotracer allows the use 
of a robust separation method giving a simple assay 
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procedure. The assay has shown good reliability in the 
hands of several operators and has been used successfully 1n 
a number of operational forensic science laboratories for 
over 1 year. 
The assay is cheap to run, the antiserum and 
radiotracer costing approximately 1.5p per test, which 1S a 
considerable saving on the Emit assay at l20p per test. In 
terms of speed, convenience and demand on the operator, the 
RIA method is favoured over the Emit technique when manual 
or semi-automated equipment is used. The method also offers 
a number of advantages over previously reported RIA methods 
through the use of a l25I-tracer and PEG for separation of 
bound and free radiotracer. 
Apart from discrepancies at low levels «20ng/ml), 
the results from the RIA method are comparable to those from 
the Emit technique. 
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CHAPTER 4 HPLC/RIA ANALYSIS OF ~9-THC AND ITS 
METABOLITES IN BODY FLUIDS 
INTRODUCTION 
The method of HPLC/RIA was first applied to the 
analysis of cannabinoids in body fluids by Williams et al. 
(1978, 1979). Although useful for research purposes, these 
methods were far from ideal in regard to routine forensic 
application, as only one sample could be assayed per day. 
Furthermore, the chromatographic method reported for plasma 
analysis (Williams et al. 1978) did not separate 
~9-THC-ll-oic acid and its glucuronide conjugate. Extensive 
modification and rationalisation of both the HPLC and RIA 
methods was undertaken (Law and Moffat 1980 and Law et al. 
1981). A stepped HPLC solvent gradient was replaced by a 
single acidic eluent, giving improved separation and 
allowing analysis of up to 3 samples per day. The three 
separate RIA procedures previously used for the analysis of 
urine, plasma and HPLC eluate were also replaced by a single 
assay. 
Although these modified methods were successfully 
applied to the routine analysis of a large number of 
forensic samples, they were not without their own 
disadvantages. The HPLC retention volumes of the 
cannabinoids were poorly reproducible, and ~9-THC-ll-oic 
acid and Il-hydroxy-~9_THCwere not separated. Perez-Reyes 
et al. (1973) have shown significant levels of this latter 
108 
metabolite following oral ingestion of ~9-THC. Isolation of 
this metabolite was therefore considered important in the 
forensic context as it could act as a marker for the oral 
route of administration. 
The development of the present 125I-RIA method prompted 
further improvements to the HPLC/RIA procedure. As the RIA 
employed a y-emitting tracer, internal standards containing 
3H or 14C (S-emitters) could be included in the HPLC 
analysis so overcoming problems of irreproducible retention 
volumes. The low energy S-particle emission would not 
interfere with the y-ray emission of the RIA tracer. 
Reversed-phase packing materials were used for the HPLC 
analysis in preference to silica or other normal phase 
material~. Large volumes of aqueous samples could be 
analysed directly, and the typical methanol/water eluents 
were suitable for direct RIA analysis. The order of elution 
on reversed-phase columns was highly predictable, being a 
function of pol~rity and lipophilic character of the 
compounds under study. 1~is chromatographic system was also 
flexible, as the retention volumes of ionisable species 
could be varied relative to neutral components, through 
changes in eluent pH. 
EXPERIMENTAL 
Development of the HPLC procedure 
Materials 
Cannabinoids were obtained from NIDA, testosterone, 
prostaglandins and their precursors, bile acids and fatty 
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acids were obtained from Sigma, Chemical Co., all other 
chemicals were Analar grade obtained from BOH. 
Equipment 
HPLC analysis was carried out using a Waters 6000A 
pump, which was used to deliver eluent to a stainless steel 
column (Shandon Southern Ltd), 5 rom i.d. x 160 or 200 mm. 
The column packing was either Hypersil 5-00S, Hypersil SAS 
(Shandon Southern Ltd) or Spherisorb 5-00S (Phase 
Separations, Clywd). Injection was made via a Rheodyne 7120 
valve fitted with a 6 ml stainless steel sample loop (0.036 
in i.d.). Columns were packed using a Shandon Packing pump 
and tested with biphenyl according to the manufacturers 
instructions. Eluate was monitored with a Cecil 212 
variable wavelength UV detector. 
Methods 
Using buffered methanol/water eluents (pH 2-7) the 
three reversed-phase packing materials were investigated for 
their ability to separate the major ~9-THC metabolites, 
using a 160 mm column. 
using a 200 rom column. 
Hypersil 5-00S was also evaluated 
Approximately 5 ~l aliquots of 
1 mg/ml ethanol solutions of cannabinoids were analysed, UV 
detection was at 220 or 270 nm. 
Various carboxy-containing compounds were investigated 
as potential internal standards for the HPLC/RIA procedure. 
Approximately 5 ~l aliquots of 1-10 mg/ml ethanolic 
solutions were analysed; UV detection was at 220 nm. 
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HPLC/RIA analysis of body fluid samples 
Materials 
[G_3H] ~9-THC (222 GBg/mmol), [1_14C] decanoic acid, 
[1_14C] dodecanoic acid (both ca. 1 GBg/mmol), and [l~, 
2 oc (n)_3H] testosterone (2.2 TBq/mmol) were obtained from 
Amersham International. [1_14C] undecanoic acid was 
synthesised from I-bromodecane and 14C02 (see Appendix). 
[7_14C] Benzoic acid (1.1 GBq/mmol) was obtained from NEN, 
Boston, Mass., U.S.A. 
A standard triton/toluene scintillant was used 
throughout, all other chemicals were of Analar grade 
obtained from BDH. 
HPLC eluent was 82.5% v/v methanol in buffer, pH 1.95, 
containing; glycine (3.5 g), concentrated hydrochloric acid 
(5 ml), water (350 ml) and methanol (1650 ml). The general 
internal standard solution contained ca. 5000 cpm each of 
14C-, decanoic, undecanoic and dodecanoic acids in 10 ~l 
ethanol. For ~9-THC analysis a solution of [G_3H] ~9-THC, 
ca. 400 cpm, (15 pg) in 10 ~l ethanol, was also used. 
Antiserum for ~9-THC analysis was obtained from 
Guildhay Antisera. ~9-THC standards were prepared in 82.5% 
v/v aqueous methanol at concentrations of 0, 0.25, 0.5, 1, 
2, 4 and 8 ng/ml. 
Equipment 
HPLC equipment was as previousiy described; eluate was 
collected using an LKB Redirac 2122 fraction collector; 3H 
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and l4C were counted using an Intertechnique SL 30 liquid 
scintillation spectrometer. 
Methods 
Urine A volume of urine (up to 3 ml) shown by prior 
RIA analysis to contain ca. 30 ng of cross-reacting 
metabolites was diluted to 3 ml with water. After addition 
of an equal volume of methanol, the sample was acidified to 
pH 2 ± 0.5 (Whatman, narrow range indicator paper) with 1M 
hydrochloric acid (ca. 0.2 ml). The internal standard 
solution (IO ~l) was added, and the prepared sample (6 ml) 
was then injected into the sample loop through a 50 ~m 
filter to remove particulate matter. The sample was 
introduced on to the HPLC column under continuous flow 
conditions and chromatographed with the acidic eluent at a 
flow rate of 2.5 ml/min. A suitable number of fractions, 
typically 30 x 0.5 ml, were collected. The first 12 
fractions, corresponding to the 6 ml of 50% vlv methanol 
injected, contained no significant peaks and were discarded. 
Aliquots (0.2 or 0.25 ml) of each subsequent fraction were 
analysed in the scintillation counter to determine the 
retention volumes of the internal standards. Aliquots 
(20 ~l) of fractions 13-30 were then analysed using the RIA 
as previously described. Each HPLC fraction was assayed 
singly to demonstrate the basic chromatographic pattern. 
Where accurate quantification of metabolites was required 
repeat analysis was performed in duplicate on appropriate 
fractions. 
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Blood - The supernatant from centrifuged blood, plasma 
or serum (typically 1 ml) was spiked with the [G_3H] ~9-THC 
in ethanol (10 ~l), vortexed and equilibrated at room 
temperature for ~ 15 min. The sample was extracted with 3 
volumes of methanol by vortexing, and allowed to stand for 
15 min before centrifugation (3 min, 9000 xg). The 
methanolic supernatant was removed, diluted to 6.0 ml with 
distilled water to give a solution containing 50% v/v of 
methanol and acidified with 1M hydrochloric acid (ca. 
0.2 m1) to pH 2 ± 0.5. The extract was spiked with the 
internal standard solution (10 ~l) prior to chromatography 
which was as decribed for urine analysis except that the 
chromatographic run was extended to 25 ml (50 fractions) to 
allow analysis of ~9-THC. Fractions 13-30 were analysed for 
cannabinoid metabolites as previously described, those 
fractions shown by scintillation analysis to contain ~9-THC 
(typically fractions 44-48), were then analysed for this 
compound using the following RIA procedure. 
RIA. 
(i) Standard or HPLC eluate (50 ~l) 
(ii) Synthetic urine (50 ~l) 
(iii) Radiotracer (100 ~l) diluted in assay buffer to 
give ca. 11,000 cpm/lOO ~l, (ca. 2.5 pg). 
(iv) Antiserum (100 ~l), Guildhay antiserum diluted 
1:3200 in assay buffer. 
The remaining assay procedure was the same as the basic 
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In certain instances, both blood and urlne samples were 
injected on to the HPLC in 1-3 ml of 50% v/v aqueous methanol 
rather than the normal 6 mI. Under these conditions, the 
cannabinoids eluted earlier, and the chromatographic pattern 
was shifted by 5-3 ml depending on the volume injected. The 
resultant variation in retention volume was corrected for, 
and the cannabinoids identified by reference to the internal 
standards. 
RESULTS AND DISCUSSION 
Development of the HPLC procedure 
The development of the HPLC and RIA procedures were 
closely linked, as the HPLC eluate needed to be in a form 
sui-table for RIA analysis. The extraction of serum with 4 
volumes of methanol, to give an extract of ca. 82.5% v/v 
methanol was partially dictated by the need to use an HPLC 
eluate of approximately this methanol concentration. HPLC 
analysis was therefore carried out using 82.5% v/v aqueous 
methanol (suitably buffered) which for the purposes of RIA 
was considered equivalent to methanol serum extracts and 
methanolic ~8-THC-ll-oic acid standards. 
Of the three stationary phases examined the SAS 
material was more difficult to pack giving columns with ca. 
35% lower efficiences than the comparable ODS columns. The 
use of the SAS material was also limited by the relatively 
high minimum pH limit of 3.5 compared with pH 1.5 for ODS 
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type materials. This factor limited the extent to which 
the retention volumes of carboxy containing metabolites 
could be increased as a function of decreasing pH. 
Figure 24 shows the variation in retention volumes for 
a number of acidic and neutral compounds as a function of 
the eluent pH. As the pH decreases, the retention volumes 
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Figure 24. The variation in retention volume with change 
. 1 t pH for neutral compounds; testosterone. , ln e uen . d' nds' ll-hydroxy-~9_THC., and ~9-T~C ~ ~ and aCl lC compou I 
decanoic acid. ; ~9-THC-ll-01C aCld •. 
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7 
of the acidic components increase while those of the neutral 
components remain relatively constant. To obtain maximum 
separation of A9_THC-ll-oic acid and ll-hydroxy-A9_THC 
whilst ensuring maximum separation of acidic components, an 
eluent pH of ~ 4.5 appeared to be necessary. However, 
Figure 25 shows that a further small improvement in 
separation of the polar metabolite and A9-THC-ll-oic acid 
500 
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F' 25. HPLC/RIA chromatograms obtained from a urine 19ure 'H Peak 
sample chromatographed at three dlfferent eluent P s. , 
A = polar metabolites, B = A9_THC-l~-~ic ~cid glucuronl~e 
and C = A9-THC-ll-oic acid. (Quantlflcatlon of metabolltes 
is approximate). 
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glucuronide can be obtained by reducing the eluent pH to 
nearer the working limit of the ODS packing material. Used 
with an eluent of 82.5% v/v aqueous methanol pH 1.95, a 
160 rom Hypersil 5-0DS column gave the best overall 
separation of the cannabinoids, and ~9-THC-ll-oic acid and 
ll-hydroxy-~9_THC in particular (Table 12). This HPLC 
system is a major improvement on those previously reported 
for ~9-THC and its metabolites (Williams et al. 1978; Abbot 
et al. 1979; Valentine et ala 1979) and may prove useful in 
combination with other detection methods in addition to RIA. 
Columns of 200 rom length, were found to be difficult to 
pack routinely; the efficiencies obtained were no better 
than those of 160 rom columns. 
In the search for internal standards suitable for the 
HPLC/RIA procedure, the only cannabinoid compound available 
with high enough specific activity was [G3-H] ~9-THC (222 
GBq/romol). A number of non-cannabinoid compounds were 
therefore also examined. These compounds were selected on 
the basis of three criteria. They had to be commercially 
available in 3-H or l4C-labelled form, they had to exhibit 
similar lipophilic character to cannabinoids, and possess a 
carboxy function to mimic the properties of the major acid 
metabolites. The compounds initially investigated on the 
basis of these criteria are shown in Table 13. Only those 
compounds having retention volumes between cholic acid 
(3.8 ml) and dodecanoic acid (6.5 ml) were initially 
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TABLE 12 
HPLC retention volumes of cannabinoids 
Compound Retention Volume (ml) 
8B,ll-Dihydroxy-~9_THC 4.0 
8a,ll-Dihydroxy-~9_THC 4.3 
8B-Hydroxy-~9_THC 4.8 
~9-THC-ll-oic acid glucuronide 5.0* 
8a-Hydroxy-~9_THC 6.6 
ll-Hydroxy-~9_THC 7.0 
~8-THC-ll-oic acid 7.5 
~9-THC-ll-oic acid 8.0 
Cannabinol 13.5 
16.8 
18.5 
Column; 160 rnrn x 5 rnrn Hypersil ODS, eluent; 82.5% v/v 
methanol in buffer, pH 1.95, detection wavelength; 220 nm, 
volume injected; 5~1. 
* . 1 Approxlmate va ue, obtained from a body fluid sample with 
RIA detection. 
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TABLE 13 
Compounds investigated as potential internal standards 
and their retention volumes in the HPLC/RIA procedure 
Compound 
Benzoic acid 
Prostaglandin E1 
Prostaglandin Al 
Cholic acid 
Decanoic acid 
(~9-THC-11-oic acid) 
Deoxycholic acid 
Dodecanoic acid 
(~9-THC) 
Arachidonic acid 
Stearic acid 
Retenoic acid 
Linoleic acid 
Retention Volume (m1) 
2.1 
2.3 
2.7 
3.8 
3.9 
(4.7) 
5.5 
6.5 
(11.4) 
13.7 
14.0 
14.0 
15.0 
Eicosa-8,ll,14-trieonic acid 18.5 
Column: 160 x 5 mm Spherisorb ODS, eluent: 82.5% v/v aqueous 
methanol, pH 2, flow rate 2 ml/min. 
119 
considered useful. However none of the compounds studied 
had a retention volume near or identical to ~9-THC-ll-oic 
acid on either Hypersil or Spherisorb ODS. Examination of 
the retention data suggested that undecanoic acid might have 
a similar retention volume to THC-ll-oic acid. This was 
borne out experimentally. The non-commercial availability 
of this compound in radiolabelled form was overcome by a 
relatively simple synthesis (see Appendix). This material 
subsequently proved most useful in acting as an exact 
retention marker for ~9-THC-ll-oic acid in routine forensic 
analysis. The commercially available ClO and C12 fatty 
acids have also proved useful. The former elutes on the 
tail of the glucuronide peak and thus acts as a retention 
marker for that compound. 
Subsequent analysis of biological samples indicated the 
presence in urine of significant amounts (~25%) of polar 
metabolites, other than ~9-THC-ll-oic acid and its 
glucuronide which cross-reacted in the RIA. During the 
initial development of the HPLC/RIA procedure, and during the 
analysis of control samples (see Chapter 5), [7_14C] benzoic 
acid, and [1«, 2«(n)-3H] testosterone were used as retention 
markers to aid the characterisation of these compounds. 
HPLC/RIA analysis of body fluid samples 
Application of the combined HPLC/RIA method to the 
analysis of urine samples from cannabis users gives a 
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typical chromatographic pattern showing three peaks (Figure 
26). Peak B which corresponds to ~9-THC-II-oic acid 
glucuronide usually predominates. However, in an alkaline 
urine sample (pH ~8) this metabolite appears to undergo 
partial or full hydrolysis (at 40 C or room temperature) to 
give the free carboxy metabolite (peak C). The first broad 
peak (A) contains at least two cross-reacting components 
which have been partially resolved with one particular HPLC 
column (Figure 27). These two compounds elute prior to both 
the dihydroxylated metabolites and the glucuronide conjugate 
on this reversed-phase system, suggesting that they are of 
high polarity. The cross-reactivity data for the RIA shows 
the antiserum to react most favourably with 8- or 
II-substituted compounds suggesting these metabolites are of 
this type. Table 14 gives the levels of cannabinoid 
metabolites typically encountered in urine samples 
submitted for forensic examination. The wide variation In 
metabolite ratios is probably attributable to the variation 
In pH of the samples. 
Analysis of blood or plasma gives the typical pattern 
shown in Figure 28. Although the overall pattern is similar 
to that from urine samples, the peak ratios are more 
reproducible suggesting greater stability of the glucuronide 
metabolite in blood or plasma. The first small peak A, 
which probably corresponds to the similar components 
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Figure 26. An HPLC/RIA chromatogram obtained from the urine 
of a person who had consumed cannabis. Peak A = polar 
metabolites, B = ~9-THC-ll-oic acid glucuronide, C = 
~9-THC-ll-oic acid. 
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Figure 27. An HPLC/RIA chromatogram obtained from the urine 
of a person who had consumed cannabis showing the presence 
of two polar metabolites. Peaks Al, A2 = polar metabolites, 
B = ~9-THC-ll-oic acid qlucuronide, C = ~9-THC-ll-oic acid. 
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TABLE 14 
Concentrations of 119_THC metabolites ln urine samples 
analysed by RIA and HPLC/RIA 
Concentration (ng/m1) 
Total Polar 119_THC-11-oic 119_THC-11-oic-
metabolites* metabo1ites+ acid glucuronide acid 
3.3 1.5 0.9 0.1 
16 7.2 trace 3.5T 
22 9.3 9.0 1.0 
28 9.3 8.0 4.6 
34 7.3 16 2.8 
43 9.0 27 3.1 
90 14 56 5.7 
107 26 53 10 
142 42 86 0 
152 57 72 30 
580 139 124 2121 
840 184 563 41 
870 103 418 
25ft 
321 128 375
T 
1060 
410 861 187 1750 
*Determined by direct RIA 
+Correspond to Peak A in Figures 26 and 27 
{Sample pH) 8 
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Figure 28. Typical HPLC/RIA chromatogram obtained from the 
blood of a person who had consumed cannabis. Peak A = polar 
metabolites, B = ~9-THC-II-oic acid glucuronide, C = 
~9-THC-II-oic acid. 
observed in urine, lS present in much smaller quantities, 
ca. 2% of the total activity compared to ca.~ 25% in urine. 
Peak B (corresponding to the glucuronide conjugate) and peak 
C (the free acid metabolite) usually occur in the ratio of 
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approximately 3:1. Table 15 gives the levels of 
cannabinoids typically encountered In serum. The value of 
rneasuring cannabinoid metabolites (concentrations up to 141 
ng/ml) is clearly demonstrated, compared to measuring only 
the concentrations of ~9-THC itself (up to 4.6 ng/ml, and 
often not present at all). The low cross-reactivity of 
~9-THC with the Emit antiserum, coupled with the low levels 
present in blood samples, made it necessary to use a 
separate, more sensitive assay for the determination of this 
compound. 
The relatively low levels of ~9-THC-ll-oic acid 
glucuronide in plasma coupled with small sample Slze has 
prevented mass spectral identification. This metabolite, 
however, does have the same retention volume as the 
glucuronide conjugate previously identified in urine 
(Williams and Moffat 1980) and can be hydrolysed using 
B-glucuronidase (type Bl) or alkali, to give free 
~9-THC-ll-oic acid (see Chapter 5). 
Recovery of cannabinoid compounds following HPLC 
separation and RIA analysis was 71% ± 11 (S.D.) for plasma 
and 85% ± 16 (S.D.) for urine, based on the original direct 
RIA result. 
Although the absolute cannabinoid retention volumes 
vary from column to column, using the method as described, 
they are highly reproducible and the chromatography shows no 
significant deterioration over at least fifteen consecutive 
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TABLE 15 
Concentrations of ~9-THC and its major metabolites ln 
serum samples, analysed by RIA and HPLC/RIA 
Concentration (ng/ml) 
Total ~9-THC-11-oic ~9-THC-11-oic ~9-THC 
metabolites* acid glucuronide acid 
17 11 2.5 2 
20 8.0 8.3 0 
22 9.9 5.9 0 
25 17 3. 1 trace 
37 7 5.4 0 
39 29 7.8 O. 5 
45 24 14 1.7 
104 63 23 1.0 
124 79 18 4.6 
141 85 40 2. 5 
*Determined by direct RIA 
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plasma analyses. To a certain extent, this makes the use of 
the internal standards (with the exception of ~9-THC) 
redundant. However, when using a new column for the first 
time, or in re-use of an old column which has dried out, 
these compounds become invaluable in allowing accurate 
identification of the chromatographic peaks. Because of the 
very low levels of ~9-THC, the use of the internal standard 
1S considered necessary in the analysis of blood, in order 
to pin-point the small chromatographic peak for ~9-THC. 
To maximise column life and minimise hydrolysis of the 
stationary phase, the column was flushed with water followed 
by methanol at the end of each working day. 
CONCLUSION 
The method described here has been successfully applied 
in a number of laboratories for the characterisation and 
confirmation of cannabinoid metabolites 1n body fluids. 
The chromatographic patterns shown in Figures 26-28 are 
considered highly characteristic of cannabis consumption, 
identification of the metabolites being based on their 
reaction with the cannabinoid specific antiserum, and their 
HPLC retention volumes. The method therefore confirms the 
presence of ~9-THC metabolites in blood and urine following 
a preliminary screen by RIA. 
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Using semi-automated equipment and fully automated data 
handling, a minimum of 6 samples can be fully processed 1n 
one day. This throughput could be further increased by the 
use of modern automated HPLC and RIA equipment. However, 
the method has proved most efficient and reliable when used 
in the manner described. The sensitivity of detection 1S 
good. Levels as low as 3.3 ng/ml cross-reacting metabolites 
in urine and 6.5 ng/ml in plasma have been confir~ed, using 
3 ml and 1 ml of sample respectively. The overall 
specificity of the method is high, being a function of the 
chromatographic separation, antiserum characteristics and 
the complex pattern of cannabinoid metabolites. 
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CHAPTER 5: THE METABOLISM AND EXCRETION OF CANNABINOIDS 
FOLLOWING ORAL INGESTION OF CANNABIS RESIN 
INTRODUCTION 
The development of analytical methods for cannabinoid 
detection and the interpretation of subsequent findings must 
be based on a firm understanding of the metabolism, 
distribution and other pharmacokinetic parameters. This is 
of particular importance with ~9-THC which is rapidly and 
extensively metabolised and not excreted in the urine. 
Although a wide variety of methods have been developed for 
the detection and quantification of ~9-THC and its 
metabolites, an incomplete understanding of ~9-THC 
metabolism in man has limited the development of the ideal 
technique for forensic use. Similarly, the lack of 
pharmacokinetic data on the major metabolites has made 
interpretation of analytical results difficult. This is 
most apparent in relation to the persistence of cannabinoids 
in blood and urine of man following cannabis use, where 
little data are available. Wall and Perez-Reyes (1981) have 
reported levels of ~9-THC and metabolites in plasma for up 
to 72 hr after cannabis consumption, but it is probable that 
significant levels of cannabinoids persist in blood and 
urine for much longer periods, possibly up to several weeks 
after cannabis use. Although the persistence of 
cannabinoids for such periods is clinically insignificant, 
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it is highly pertinent to the forensic toxicologist. 
Workers in this field are frequently required to give an 
interpretation of such findings, especially in relation to 
time since consumption of the cannabis preparation, and 
ultimately the psychological status of the sUbject. In many 
instances, body fluid samples are obtained many hours or 
days after an alleged offence was committed. The following 
experiment was carried out in order to give a more complete 
understanding of cannabinoid metabolism and thus aid the 
forensic toxicologist in his interpretation. 
Oral administration was chosen for this initial study, 
as experiments could be carried out easily on reliable, 
non-cannabis users who were willing to provide blood and 
urine samples over a prolonged period, whilst omitting 
further cannabis use. Unlike smoking of cannabis, the 
absorption of ~9-THC following oral ingestion would not be 
seriously affected by the naive status of the subjects. 
Administration of cannabis resin rather than pure 
~9-THC was selected to mimic the conditions normally 
encountered in forensic cases. 
EXPERIMENTAL 
Protocol for cannabis administration 
Materials 
Cannabis resin typical of the type produced in Pakistan 
was obtained from the Laboratory of the Government Chemist. 
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This had been shown by GLC and HPLC analysis (Baker et ale 
1980 and 1981) to contain 69-THC (6.1%), 69-THC acids 
(5.4%), cannabinol (0.7%) and cannabidiol (5.6%). 
Volunteers 
These were males aged 27-34, average weight 71 kg, who 
were shown to be in good physical and mental health and who 
had no previous experience of cannabis use. None of the 
subjects were taking other drugs and all abstained from 
alcohol use for at least 24 hrs prior to, and after the 
experiment. The experimental protocol was approved by the 
Committee on the Safety of Human Experiments, Chemical 
Defence Establishment, Porton Down, Wilts. 
Dose and administration of cannabis reSln 
The experiment was divided into two separate trials 26 
days apart. The first trial involved a low cannabis dose 
and was designed to assess the reaction of the subjects to 
cannabis exposure. The second trial involved a typical 
cannabis dose, i.e. 20 mg 69-THC. 
Trial 1 Each of five subjects took 69-THC (5.0-5.2 mg) ln 
cannabis resin (ca. 84 mg). The resin was cut into small 
pieces (ca. 8 mm3 ) and mixed with the filling in a meat 
sandwich. The subjects were monitored for adverse 
reactions. Pulse rate and conjunctival suffusion were 
measured at regular intervals for up to 4.5 hrs after 
ingestion. Urine samples were collected at intervals during 
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the first 12 hrs following ingestion and daily thereafter 
for up to 8 days. 
Trial 2 Each of 4 subjects took ~9-THC (20mg) in cannabis 
reSln (ca. 330 mg) as in trial 1. 
The subjects were continuously monitored by 
electro-cardiography and pulse rate and blood pressure were 
measured at regular intervals. Conjunctival suffusion and 
euphoric state were independently assessed. 
Venous blood samples were obtained at regular intervals 
for up to 8 hours, and venous and capillary blood samples 
were taken daily for up to 5 days after ingestion. Samples 
were taken into heparinised containers, venous blood samples 
were separated immediately to obtain plasma, capillary 
samples were stored at 40 C prior to separation. 
Urine samples were taken regularly for up to 12 hrs 
after consumption and daily thereafter for up to 14 days. 
All samples were stored at -18o C prior to and between 
analyses. 
Body fluid analysis 
Materials and equipment 
These were as described in Chapters 3 and 4. 
Methods 
RIA analysis of urine and plasma samples for total 
cannabinoids was carried out as described in Chapter 3. 
~8-THC-ll-oic acid was used as the RIA standard and all 
levels quoted are relative to this compound. 
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The HPLC/RIA procedure was as described in Chapter 4. 
As well as the 14C-fatty acids, [1_14C] benzoic acid and 
[la, 2a (n)_3H] testosterone were also added to the urine 
samples and plasma extracts as internal standards. 
Urine samples were also analysed for creatinine content 
using a commercial kit (Instrumentatl'on L b t S A a ora ory .p .. , 
20037 Paderno Dugnano, Italy). 
Characterisation of plasma ~9-THC-II-oic acid glucuronide 
Materials 
Bovine B-glucuronidase (Type Bl) and phenolphthalein 
glucuronide were obtained from Sigma Chemical Co. 
The residue of HPLC fractions containing the suspected 
glucuronide were obtained following analysis of the control 
plasma samples. The fractions were combined to give 1.5 ml 
of solution, which was shown by RIA analysis to contain ca. 
10 ng/ml cross-reacting cannabinoids. 
Method 
Aliquots (0.25 ml) of the suspected glucuronide 
solution were dried down under nitrogen ( <400 C) and the 
residues treated in the following manner. 
Enzymic hydrolysis - The residue was dissolved ln 0.05 M 
phosphate buffer (50 ~l, pH 5) and to this was added bovine 
glucuronidase solution (50 ~l, 20 mg/ml) in buffer, or 
buffer alone (negative control). To each solution was added 
phenolphthalein glucuronide solution (1 ~l, 10 mg/ml) in 
water. After incubation at 370C for 20 hrs, an aliquot 
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(10 ~l) of each reaction was added to molar sodium hydroxide 
solution (25 ~l) to test for hydrolysis of the 
phenolphthaleine conjugate. The samples were then diluted to 
1 ml with 50% v/v methanol. After centrifugation to remove 
insoluble protein material the solutions were acidified 
(pH 2) with molar hydrochloric acid (25 ~l), spiked with 3H 
and l4C internal standards and analysed by the HPLC/RIA 
procedure. 
Basic hydrolysis - The residue was dissolved in 50% v/v 
aqueous methanol (0.1 ml) to which was added 10 M sodium 
hydroxide solution (10 ~l). The mixture was heated in a 
sealed vial at 1000C for 15 mln, and after cooling the 
sample was diluted and adjusted to 1 ml with 50% v/v aqueous 
methanol. After acidification (pH 2) with conc. 
hydrochloric acid (10 ~l) and spiking with the internal 
standards the sample was analysed by HPLC/RIA. 
Stability of cannabinoids in urine 
To determine the stability of the ur1nary metabolites, 
a single urine sample was divided and stored at 40 C and room 
temperature (12-240 C) with and without the addition of 
dilute ammonium hydroxide. The base-treated samples 
attained a pH of 8.5, untreated samples were pH 5.7. 
RESULTS 
Clinical signs 
In the first trial, none of the subjects reported any 
psychological effects or demonstrated any reaction normally 
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associated with cannabis. One subject demonstrated 
physiological effects which may have been due to cannabis. 
These included faintness and pallor and the subject was 
excluded from further study. 
In the second trial, all subjects exhibited 
physiological signs of cannabis intoxication; tachycardia 
and conjunctival suffusion. Three of the subjects reported 
feeling "high", with typical psychological effects. The 
fourth subject reported a moderate adverse reaction. These 
effects commenced at approximately 2 hr, and lasted for up 
to 8 hr after consumption of cannabis. 
Plasma analysis 
The plasma cannabinoid elimination curves for the four 
subjects measured by direct RIA are given in Figure 29. 
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t' determined by 
Fl'gure 29. Plasma cannabinoid concentra lons 9 THe 
, t ho ate 20 mg 6 -direct RIA analysis for four subJec s w 
in cannabis resin. 
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After reaching a peak, at ca. 4-6 hr after ingestion, the 
level of plasma cannabinoids in each of the four subjects 
showed a relatively smooth decline over the next 5 days. 
The assay could clearly distinguish between low levels ca. 3 
ng/ml and cannabinoid free plasma. 
Analysis by HPLC/RIA enabled quantification of parent 
~9-THC, as well as ~9-THC-ll-oic acid and its glucuronide 
conjugate. Table 16 gives the mean concentrations following 
analyses of the venous plasma samples taken up to 3 days 
TABLE 16 
Mean concentrations of ~9-THC and metabolites in the 
plasma of four subjects who ate 20 mg ~9-THC in cannabis resin. 
Time after 
ingestion 
(hr) 
1 
2 
4 
6 
8 
24 
48 
72 
Total 
metabolites+ 
11 ± 3.5 
54 ± 10 
146 ± 20 
132 ± 5.0 
111 ± 7.9 
52 ± 9.4 
25 ± 5.1 
13 ± 3.4 
* value ± S E M n Mean , 
~easured by direct RIA 
Concentration ng/ml* 
~ 9-THC-11-oic 
acid glucuronide 
3.4 ± 1.1 
26 ± 3.4 
107 ± 16 
99 ± 8.3 
80 ± 10 
31 ± 1.3 
17 ± 3.9 
9.1 ± 2.7 
= 4 
analysis 
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l:I 9-THC-11 
-oic acid 
6.6 ± 2.1 
23 ± 6.3 
38 ± 10 
29 ± 4.7 
24 ± 5.6 
14 ± 2.5 
6 ± 2.0 
3.3 ± 0.9 
1.5 ± 0.2 
3.9 ± 1.1 
6.9 ± 1.4 
3.0 ± 0.9 
1.8 ± 0.4 
0.5 ± 0.1 
0.2 ± 0.1 
O. 1 ± 0.1 
after consumption of cannabis. The low levels of ~9-THC 
detected (~10 ng/ml) and the marked inter-individual 
variation are similar to those reported by Ohlsson et al. 
(1980) following oral ingestion of ~9-THC. In those 
samples taken within two hours of consumption, 
Il-hydroxy-~9_THC was detected at concentrations comparable 
to ~9-THC itself. Accurate quantification of this 
metabolite was not possible owing to incomplete separation 
from the more significant ~9-THC-ll-oic acid metabolite 
(Figure 30). The major proportion of cannabinoid activity 
in the plasma was due to ~9-THC-ll-oic acid glucuronide (see 
next section), and to a lesser extent the free acid itself. 
However the ratio of these two compounds changed with time. 
After 4 hr the concentration of the glucuronide exceeded 
that of the free acid, and the HPLC/RIA chromatograms were 
similar to those obtained from forensic samples (Figure 28). 
It lS highly significant that around 75% of the total 
cannabinoid material detected in the plasma was in 
conjugated form, and in one subject this was as high as 85% 
during the later part of the experiment. Least squares 
analysis of the concentration data over the period 8-72 hr 
gave distribution half lives for ~9-THC-ll-oic acid and its 
glucuronide of 22 ± 2 hr and 21 ± 2 hr respectively (mean 
± SEM, n = 4). This is the first report of such data. 
Characterisation of plasma ~9-THC-ll-oic acid glucuronide 
The negative control sample showed on analysis a singl~ 
peak due to unchanged suspected glucuronide. The samples 
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Figure 30. An HPLC/RIA chromatogram showing a low 
glucuronide/free acid ratio obtained from the plasma sample 
of subject I taken 1 hr after ingestion of cannabis resin, 
Peak A = polar metabolite(s), B = ~9-THC-ll-oic acid 
glucuronide, C = ~9-THC-ll-oic acid, D = Il-hydroxy-~9-THC 
and E = ~9-THC. 
treated with glucuronidase and base showed a complete 
absence of this compound. However both samples did show the 
same distinct peak at the retention volume of ~9-THC-ll-oic 
acid. 
Urine analyses 
Following dosing with 5 mg ~9-THC (Trial 1), maximum 
levels of urinary cannabinoids were attained between 8-10 
hr after ingestion, these ranged from 112-210 ng/ml 
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cross-reacting cannabinoids. Significant positive results 
were obtained for a further 7 days after consumption. 
Following the oral dose of 20 mg ~9-THC, urine levels 
rose to between 185-1063 ng/ml cross-reacting cannabinoids 6 
hours after ingestion, with positive results being obtainect 
for at least a further 12 days. In both trials, metabolites 
appeared in the urine within 1-2 hr of ingestion. 
HPLC/RIA analyses of a number of the samples from the 
four subjects produced a surprising result. In contrast to 
plasma, ~9-THC-ll-oic acid was found to be a minor 
metabolite comprising less than 4% of the total urinary 
cannabinoid activity. The major proportion of the urine 
metabolites (ca. 65%) was due to the glucuronide conjugate, 
the remainder being due to more polar material. Figure 31 
shows a typical urine elimination curve of total metabolites 
for one of the four subjects. Determination of creatinine 
concentrations allowed adjustment of the cannabinoid levels 
for variations in urine flow rate. From the straight line 
portion of the adjusted elimination curves, a urinary 
half-life for total metabolites has been calculated as 
25 ± 1 hr (mean ± SEM, n = 4). 
Stability of cannabinoids in urlne 
A urine sample from one of the volunteers, shown on 
initial analysis to contain the glucuroniJe but to be free 
of ~9-THC-ll-oic acid, was found to contain a significant 
quantity of the latter metabolite after storage at room 
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Figure 31. Urinary cannabinoid concentrations for a subject 
who ate 20 mg 6 9-THC in cannabis resin; concentration of 
cannabinoids (e), ratio of concentrations of cannabinoins to 
creatinine (.). 
temperature for 12 days. When stored at pH 8.5 the 
hydrolysis of the glucuronide was more pronounced, with 13% 
of the total activity being due to ~9-THC-ll-oic after a 4 
day storage period at the same temperature. A similar 
though less marked change was observed with the alkaline 
sample stored at 40 C. 
A second effect, due to prolonged storage (90 days at 
room temperature) resulted in the loss of ca. 70% of the RIA 
cross-reactivity in both the samples (pH 5.7 ann 8.5). At 
4 0 C, the untreated sample (pH 5.75) showed no loss of 
activity, whilst that at pH 8.5 showed ca. 50% loss. 
DISCUSSION 
Metabolism 
The conversion of the major polar plasma metabolite to 
~9-THC-ll-oic acid on treatment with base or glucuronidase 
is strong evidence for the identification of this compound 
as ~9-THC-ll-oic acid glucuronide. This tentative 
identification is further supporteo by the fact that the 
compound has been previously identified in human urine as a 
major ~9-THC metabolite (Williams and Moffat 1980). The 
relatively low levels of the gluruconioe present in plasma, 
coupled with the small sample size has precluded any 
attempts at mass-spectral identification. Although a number 
of metabolites have been characterised and quantified 
following cannabis use, this would appear to be the first 
report on concentrations of a metabolite conjugate followinq 
controlled consumption of cannabis. 
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The concentration of the glucuronide in plasma, 
although initially exceeded by the concentration of the free 
acid, rose gradually until it constituted approximately 75% 
of the total plasma cannabinoid content measured by the RIA. 
This has important consequences for analytical method design, 
as those techniques directed towards the unconjugated 
material alone (Nordqvist et ale 1977, Cook et ale 1982 and 
Foltz et ale 1982) are seriously underestimating plasma 
metabolite levels, and the sensitivity of such methods is 
therefore limited. 
The metabolite pattern observed in urine samples was 
markedly different to that seen in plasma. Al though the 
glucuronide conjugate was the major urinary metabolite, the 
free acid was of minor importance heing present in only low 
concentrations in fresh samples. It is possible, however, 
that even these low levels could be artifacts, given the 
susceptibility of the glucuronide to hydrolysis. These 
experiments would also explain the high concentrations of 
free acid in those samples submitted for forensic analysis 
and the total absence of glucuronide in those samples with 
high pH (see Chapter 4). 
The use of a broadly specific assay capable of 
detecting glucuronide conjugates, or hydrolysis of the 
sample prior to the analysis of free ~9-TBC-ll-oic acid, is 
therefore recommended for forensic work. The failure to 
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adopt such procedures accounts for the poor correlation 
between broadly specific immunoassay methods and GC in 
recent reports on cannabinoid analysis (O'Connor and Rejent 
1981 and Peat et al. 1982). 
Stability of urine metabolites 
The data here extend that from Chapter 3 which showed 
urlne metabolites to be relatively stable at 40 and -180 C. 
These experiments suggest that storage of unsterile urine at 
room temperature or 40c is responsible for the loss of 
urinary cannabinoid cross-reactivity, especiallY if the 
urine has a high pH. The loss in cross-reactivity is also 
accompanied by hydrolysis of the glucuroni(le conjugate which 
is particularly unstable when stored in urine at room 
temperature under alkaline conditions. 
Interpretation 
Following a single, moderate, oral dose of cannabis 
(20 mg ~9-THC), significant concentrations of cannabinoid 
metabolites were detected in plasma samples for up to 5 days 
and in urine samples for at least 12 days; long after 
pharmacological action had passed. The results for urine 
are in general agreement with a recent report which showed 
that chronic cannabis use can lead to detectable urinary 
cannabinoid levels up to 36 days after termination of use 
(Dackis et al. 1982). In that study analyses were carried 
out using a commercial enzyme immunoassay (Emit). Also of 
significance is the fact that a small dose of cannabis (5 mg 
143 
~9-THC) can glve relatively high urine cannabinoid levels 
(up to 210 ng/ml cross-reacting cannabinoids) without the 
subject having experienced any pharmacological effect. 
These results have important implications for forensic 
toxicologists who are frequently requested to interpret such 
findings in cases of drug-related crime. Estimates of time 
since ingestion derived from a single analytical result, 
especially from urine analyses, will probably be so broad as 
to be of little evidential value. Furthermore, it is very 
difficult to state whether the donor of the specimen 
achieved a state of "high", let alone indicate whether the 
subject was under the influence of cannabis at the time of 
any alleged offence or accident. 
The major active principle of cannabis, viz. ~9-THC, 
persisted in detectable concentrations in plasma for at 
least 24 hr after consumption. This result is in accord 
with recent work (Ohlsson et ale 1980, Cocchetto et ale 
1981, Hollister et ale 1981 and Perez-Reyes et ale 1982) 
which indicated a poor correlation between the period of 
pharmacological action and ~9-THC plasma levels. Forensic 
scientists are often requested to interpret plasma 
cannabinoid levels and give an indication of their likely 
psychopharmacological effects. From the above results it 
appears that there is no simple parameter which can be used 
for this purpose. Other analytical parameters which might 
be more highly correlated with the period of pharmacological 
action were therefore examined. 
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drug/metabolite and metabolite/metabolite ratios 
have been shown to be useful In determining the time since 
ingestion of diazepam (McBurney 1981). This form of data 
manipulation was applied to the question of cannabis 
consumption, initially by examining the plasma 
glucuronide/free acid ratio. (The glucuronide lS stable in 
plasma unlike the situation in urine). The value for this 
parameter rose during the first 6-10 hr after consumption, 
then remained approximately constant. Although all four 
subjects gave an initial glucuronide/free acid ratio of <1, 
at 9 hr after ingestion there was marked inter-individual 
variation in the value of the ratio which ranged from 2-7. 
In those rare instances where two blood samples are obtained 
from a subject, this ratio could be useful. A higher 
glucuronide/free acid ratio in the second sample could 
suggest recent consumption of cannabis, i.e. 1-10 hr 
previously, a period which closely matches the period of 
pharmacological action following oral ingestion. 
A more useful function was found in the total 
metabolite/ ~9-THC ratio. As expected, the numerical value 
of this parameter increased throughout the experimental 
period. However, it was relatively low and constant during 
the first 4 hr after consumption (Figure 32), overlapping 
the period of most pronounced pharmacological action, and 
rose rapidly thereafter. A total metabolite/~9_THC ratio of 
<20 may therefore indicate recent oral consumption of 
cannabis. 
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Figure 32. Variation in the [total metaboliteJ/[~9_THCJ 
ratio with time after ingestion, mean ± SEM for four 
subjects. 
Further work is obviously necessary to validate this 
type of approach, especially by extending the number of 
subjects used and examining cannabis smoking where the 
pharmacokinetics may be significantly different. If 
subsequently proved valid, it may still be limited by the 
effects of multiple dosing with cannabis which will tend to 
produce a steady state total metabolite/ ~9-THC ratio >20. 
\. A s; ,,·,lA'- form of data manipulation using the ~9-THC-ll-oic 
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acid/6 9-THC ratio has been recently shown to g1ve similar 
results, following administation by smoking (Hanson et ale 
1983). 
CONCLUSION 
The work presented here has important implications for 
forensic toxicologists and workers in the field of 
cannabinoid metabolism. 69-THC-ll-oic acid glucuronide was 
shown to be a major plasma metabolite of 6 9-THC, being 
present at levels exceeding the free acid. The same 
compound predominated in urine, with the free acid 
constituting only a few percent of the total urine 
cannabinoid cross reactivity. Even these low levels of free 
acid may have been due to hydrolysis of the glucuronide on 
storage or handling. 
To maximise sensitivity of detection, urlne and plasma 
samples should be hydrolysed prlor to analysis for 
69-THC-ll-oic acid. This approach would also give better 
agreement between the broadly specific techniques (e.g. Emit 
and RIA) and more specific methods. 
Apart from stating that the donor has consumed 
cannabis, {with due regard to possible passive inhalation} 
interpretation of cannabinoid body fluid levels is extremely 
limited. However, the determination of the plasma total 
metabolite/69-THC ratio may allow estimation of time since 
ingestion and hence psychopharmacological status of a 
subject in certain instances. 
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CHAPTER 6 PASSIVE INHALATION OF CANNABIS SMOKE 
INTRODUCTION 
When cannabis 1S smoked, a significant proportion of 
the cannabinoids (ca. 25%) are not inhaled but lost to the 
room air in the side-stream smoke (Truitt 1971). Fish and 
Wilson (1969) have identified three cannabinoids, including 
69-THC, in airborne particulate matter (>O.l~m diameter) of 
side-stream smoke following smoking of cannabis cigarettes. 
This, together with reports on the absorption of nicotine by 
non-smokers 1n a normal tobacco smoke containing environment 
(Horning et ale 1973, Feyerabend et ale 1982) has raised the 
possibility of passive inhalation of cannabis smoke. It has 
been suggested that non-smokers occupying the same room as 
cannabis smokers could passively inhale cannabis vapours dnd 
thus inadvertently achieve significant blood and/or urine 
cannabinoid concentrations. This argument has been used as 
a line of defence in courts of law, where the results of 
cannabinoid body fluid analysis have been presented as 
evidence to support a charge of prior-possession of a 
cannabis preparation (Law 1981, unpublished results). 
Although most workers in the field considered passive 
inhalation of cannabis to be insignificant, there has been 
until recently, insufficient data for this assumption to be 
tested. 
Prior to the work described here, only one previous 
report concerning passive inhalation of cannabis had 
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appeared in the literature (Zeidenberg et ale 1977). For 
various reasons, this work is considered unsatisfactory, it 
has been given little credence and has received scant 
attention from workers in the field. 
Theoretical calculations have been attempted in an 
effort to predict likely cannabinoid levels following 
passive inhalation. The complexity of the problem, ln 
particular the approximations regarding the efficiency of 
cannabinoid absorption in passive inhalers prevented a 
satisfactory conclusion. 
To obtain a clearer understanding of the problem the 
following experiment was conducted. 
EXPERIMENTAL 
Cannabis exposure 
Materials 
Cannabis reSln containing ~9-THC (4.5%) was obtained 
from the Laboratory of the Government Chemist. Five 
hand-rolled cigarettes (ca. 8cm x O.5mm dia. weight ca. Ig) 
complete with cardboard filter were prepared using Golden 
Virginia tobacco and Rizla cigarette papers. The cigarettes 
contained an average of 151mg cannabis resin (6.8mg ~9-THC). 
Volunteers 
These were males, aged 27-38 yr who were in good 
physical and mental health and of average height and weight. 
Only one subject was a cigar/cigarette smoker. 
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Method 
The four subjects were glven the freedom of a 
well-sealed room, volume 39,500 1, in which the 5 cigarettes 
were simultaneously burnt. To facilitate burning, air was 
intermittently blown through the cigarettes using a small 
electric air pump. The cigarettes were burnt to completion 
in a total time of 30 min, and during this period a 
domestic cooling fan was used to circulate the room alr. 
Entrance and exit of the subjects to the experimental 
room for body fluid collection was carefully controlled to 
prevent excessive loss of smoke. 
Venous blood samples were taken from each subject prior 
to the experiment and at 10 min and 60 min after the last 
cigarette had finished burning. Urine samples were taken 
prior to the experiment and at 60 min and 180 min. Blood 
samples were centrifuged and the plasma and urine samples 
were stored at 40C prior to analysis the same or the 
following day. 
Body fluid analysis 
Method 
Urine samples were analysed using the Emit-d.a.u. 
cannabinoid assay, and urine samples along with plasma 
samples were also analysed by the previously described RIA 
methods (Law and Moffat, 1980 and Law et al. 1981) which 
utilised a 3H-tracer. 
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RESULTS AND DISCUSSION 
Both the blood and urine samples from all four subjects 
taken after exposure to cannabis smoke showed complete 
absence of cannabinoid cross-reactivity when assayed by the 
immunoassay methods. The results were indistinguishable 
from those of the control samples taken prior to the 
experiment. Under the experimental conditions defined 
therefore, passive inhalation of cannabis smoke did not leao 
to detectable concentrations of cannabinoids in blood or 
urlne. 
Certain conditions of the experiment, such as the 
simultaneous burning of the cigarettes was a factor 
favourable to passive inhalation, as this process is 
normally carried out sequentially in social cannabis abuse. 
A total of 34mg 6 9-THC was burnt, and the mass of the 69-THC 
in the cigarettes was representative of typical British 
cannabis smoking habits. The room volume, 39,600 1 
(including 4 desks and filing cabinets) was comparable to 
the average domestic living room. 
During the burning process, the atmosphere in the room 
became thick and smoky and generally unpleasant. None of 
the s~bjects exhibited or reported any signs associated with 
cannabis intoxication, although they did report mild eye anJ 
throat irritation. It is possible therefore, that 
exaggerated conditions designed to be more favourable to 
passive inhalation may become intolerable especially if the 
passive subjects are not cigarette smokers. 
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Subsequent to, and in contrast to this result, recent 
studies (Wethe et ale 1982 P R 
, erez- eyes et ale 1983 and 
Mason et ale 1983) have shown that passive inhalation of 
cannabis can occur, albeit under extreme conditions. In the 
study of Wethe et ale (1982), a total of 90mg ~9-THC was 
burnt in a small car. ~9-THC was detected in the blood of 
passive inhalers immediately after cessation of smoking and 
positive results using Emit were obtained from urine samples 
for a further two days. The other reports indicated that 
under less exaggerated conditions, low transient levels of 
~9-THC and metabolites could be detected in blood and urine. 
CONCLUSION 
The results of this experiment, taken with other 
published data, shows the problem of passive inhalation to 
be a complex one. The results are dependent on the mass of 
cannabis smoked, room size, residence time in the room as 
well as the sensitivity and specificity of the analytical 
technique. 
It is obviously necessary that any technique used in 
forensic practice - including the RIA reported in this 
thesis - be evaluated to assess the possibility of positive 
results being obtained following passive inhalation. 
Ideally a series of systematic experiments should be 
conducted with increasing mass of cannabis and/or decreasing 
room Slze. In this way the minimum conditions necessary for 
passive inhalation to yield positive results could be easily 
determined. A similarly useful experiment, though more 
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difficult to carry out, would be to determine the maximum 
possible levels attainable through passive inhalation. In 
practice however, although assay cut-off levels can always 
be raised to cover the likelihood of passive inhalation, 
even under the most extreme conditions, it may not be 
possible to eliminate the likelihood of passive inhalation 
in all circumstances. 
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Chapter 7 - GENERAL DISCUSSION AND CONCLUSION 
The initial lack of success in producing a useful 
radio-tracer was partially due to the lack of chemical 
characterisation of the ~9-THC hemisuccinate derivative by 
Teale and his co-workers (Teale et ale 1975). In the 
development of an RIA it is necessary to characterise all 
derivatives in the preparation of the lmmunogen or 
radio-tracer. In the case of the latter this usually 
entails production of the natural 1271 derivatives. This 
philosophy, which was successfully adopted here enabled 
identification of a significant reaction byproduct; 
isobutyl-2(2-iodoimidazo)-4-yl-ethylcarbamate. With the 
l27I-derivative identified, the reaction conditions were 
modified thereby increasing the efficiency of radio-tracer 
production using 1251. The tracer, ~8-THC-ll-oic 
acid-[125IJ iodohistamide, was produced in relatively good 
yield with high specific activity, and was shown to be 
chemically stable for at least 4 months. It is now prepared 
routinely at the Central Research Establishment and supplied 
to operational forensic laboratories in the UK. 
The problems encountered with the solubilisation of the 
tracer, the separation method and the non-equivalence of 
sample and standard were complex and closely related. 
work demonstrates the difficulty in optimising such 
multiparameter systems. Although few satisfactory 
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This 
conclusions were obtained in this area, a number of useful 
factors regarding solubilisation and optimal separation 
methods were noted. 
In practice the RIA has adequate sensitivity, and the 
broad specificity allows detection of the major ~9-THC 
metabolites. The method has been found to be convenient and 
reliable. It lS now used routinely by six operational 
forensic science laboratories in the United Kingdom. 
The combination of RIA and HPLC often appears to be a 
complex and time consuming technique. However, it possesses 
a number of advantages, and is probably superior to GC/MS in 
some respects. It has good sensitivity, excellent 
reliability and allows identification and quantification of 
a number of metabolites. This method has been most 
successfully employed at CRE and is now in use In a number 
of operational laboratories. The current throughput of 6 
samples per day could be increased by the use of automated 
equipment, further improving efficiency. 
Using the methods developed, new information has been 
obtained on cannabinoid metabolism and pharmacokinetics with 
direct relevance to forensic toxicology. ~9-THC-ll-oic acid 
glucuronide has been shown to be a major ~9-THC metabolite. 
It is the most significant compound detected in either 
blood or urine, using this technique. 
Interpretation of toxicological data has always been a 
problem area for the practising toxicologist. This is most 
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notable in attempts to predict the psychopharmacological 
status of a subject 1n drugs/driving cases from the results 
of blood analysis. The correlation presenteo between the 
total metabolite/~9_THC ratio and time since ingestion 
following oral dosing with cannabis resin should make a 
significant contribution to this area of research. 
Interpretation of total metabolite concentrations alone 
is most difficult since cannabinoids are detected in blood 
for 5 days and urine for up to 12 days after a single 
moderate dose of ~9-THC (20mg). The problems of 
interpretation are further complicated by the possibility of 
passive inhalation of cannabis smoke. Although the 
experiment reported here showed passive inhalation to be 
insignificant, the problem is variable and complex as shown 
by other published findings in contradiction to this work. 
With regard to future work, a number of areas require 
further investigation. The human experiments need to be 
extended to administration by smoking. Under these 
conditions metabolism may well differ from that observed 
with the oral route. The pharmacokinetics will also be 
different, thus affecting the interpretation of total 
metabolite/~9_THC ratios. 
Work is currently being undertaken to investigate the 
problem of passive inhalation using the 125I-RIA. 
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APPENDIX 
SYNTHESIS OF [1_14C] UNDECANOIC ACID 
EXPERIMENTAL 
Materials 
Magnesium (98%), l-bromodecane (98%), iodine and ether 
(A.C.S. reagent, absolute) were obtained from Aldrich 
Chemical Co., l4C02 (specific activity 2.l8GBq/mmol) was 
obtained from Amersham International pIc. All glassware was 
thoroughly dried prior to use. 
Method 
l-Bromodecane (350 ~l, 2.3 mmol) was dissolved ln ether 
(1 ml). A small aliquot of this solution was added to 
magnesium (4l mg, 1.71 romol) in a dry round bottomed flask 
followed by a small crystal of iodine. The mixture was 
warmed gently and the remaining l-bromodecane solution 
added. The flask was fitted with a reflux condenser and a 
calcium chloride trap, and the mixture refluxed till no more 
magnesium would dissolve (ca. 3 hr). The ethereal solution 
was then transferred to a sealed evacuated tube containing 
solid 14C02 (0.78 mgt 17 ~mol, 1 mCi) at liquid nitrogen 
temperature. The mixture was allowed to come to room 
temperature, where it was maintained for 3 hr with 
occasional refreezing to ensure efficient mixing. The ether 
was further diluted to ca. 5 ml and washed with distilled 
water (2 x 2 ml) and then dried with anhydrous sodium 
sulphate. The solvent was removed by evaporation under 
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vacuum ( <400 ) and the residue dissolved in ethanol. The 
ethanolic solution was maintained at -180 C for 48 hr and the 
insoluble crystalline precipitate of decane was removed by 
filtration. Radiochemical purity of the final product 
[1_14 C] undecane as determined by HPLC (150 mm x 5 mm 
Hypersil ODS, eluent 82.5 %v/v aqueous methanol pH 1.95) was 
estimated to be >99%. This material was used for HPLC/RIA 
analysis without further purification. 
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